Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL)──────────# Beta Finch Podcast Script: Lowe's Q4 2026 Earnings Breakdown**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into conversations you can actually follow. I'm Alex.**JORDAN**: And I'm Jordan. Today we're diving into Lowe's fourth quarter 2026 results, and there's quite a bit to unpack here.**ALEX**: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. Now, let's talk Lowe's. Alex, what were the headline numbers that caught your attention?**ALEX**: Well, Lowe's delivered $20.6 billion in Q4 sales with comparable sales up 1.3%, which is actually pretty solid given the challenging environment they're operating in. For the full year 2025, they hit $86.3 billion in sales with adjusted earnings per share of $12.28 - that's a 2% increase year-over-year.**JORDAN**: What I found interesting is how they managed to hold their adjusted operating margins flat despite some serious headwinds. CEO Marvin Ellison was pretty candid about the challenging macro environment - consumers are still hesitant about big-ticket DIY projects, and the housing market remains under pressure from high mortgage rates.**ALEX**: Speaking of headwinds, they made some tough decisions too. Lowe's announced they're eliminating about 600 corporate and support roles as part of what they call their "perpetual productivity improvement" initiatives. But here's what's notable - they're simultaneously giving out $125 million in discretionary bonuses to frontline workers.**JORDAN**: That's a fascinating contrast, isn't it? Cut corporate overhead while rewarding the people actually serving customers. It shows they're being very strategic about where they're investing versus where they're cutting costs.**ALEX**: Exactly. And speaking of investments, let's talk about their growth engines. Three areas really stood out: Pro customers, online sales, and home services. Online grew 10.5% in the quarter, and they set new records on Black Friday and Cyber Monday. Their Lowe's app was actually the number one free shopping app on Apple's App Store on Black Friday.**JORDAN**: The Pro business momentum is really interesting too. They're expanding their Pro sales force and rolling out this AI-enabled "Pro Companion" tool that helps sales associates prepare for customer conversations. It gives them instant access to relevant information so they can walk into meetings with recommendations already prepared.**ALEX**: And then there are the big acquisitions - Foundation Building Materials, or FBM, and Artisan Design Group, or ADG. Together, these are expected to contribute about $8 billion in sales for 2026. The strategy here is to create what Ellison calls a "total home" solution for builders - basically everything they need for interior spaces.**JORDAN**: Though it's worth noting these acquisitions are diluting operating margins by about 30 basis points in 2026, or 50 basis points on an annualized basis. But management says they're earnings accretive overall, which is the key metric.**ALEX**: Let's talk guidance because this is where things get interesting. For 2026, they're forecasting sales between $92 billion and $94 billion, with comparable sales flat to up 2%. That's a wider range than they usually provide.**JORDAN**: Right, and when an analyst asked about that wider range, Ellison was pretty transparent. He said there are just too many variables - unpredictable tariffs, high interest rates, and uncertain consumer demand. They're essentially saying "we're confident we'll outperform the market, but the market itself is really hard tThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────**Beta Finch Podcast Script - Gilead Q1 2026 Earnings**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Gilead Sciences' first quarter 2026 results - and wow, what a quarter this was for the biotech giant.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Jordan, Gilead came out swinging with some pretty impressive numbers, didn't they?**JORDAN:** Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.**ALEX:** And they're not just talking the talk - they're raising guidance across the board. What stood out to you most about their updated outlook?**JORDAN:** The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!**ALEX:** That's remarkable. Let's break down what's driving this HIV success, because it seems like Gilead is firing on all cylinders here.**JORDAN:** It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.**ALEX:** And during the Q&A, management seemed pretty confident about Yes2Go's trajectory. What are they seeing that makes them so optimistic?**JORDAN:** Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.**ALEX:** Now, Gilead wasn't just focused on HIV this quarter. They made some major acquisition moves. Can you walk us through what they're buying and why?**JORDAN:** This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.**ALEX:** That's a lot of cash! How are investors supposed to think about these deals?**JORDAN:** Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.**ALEX:** Speaking of Trodelvy, how's their existing oncology business performing?**JORDAN:** Trodelvy is growing nicely - up 37% year-over-year to $402 million. They're expecting regulatory decisions this year that could expand its use to first-line breast cancer treatment, which would be a significant maThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: PHARMA (https://betafinch.com/groups/PHARMA)──────────# Beta Finch Podcast Script: Zoetis Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.**JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?**JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.**ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?**JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.**ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?**JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.**ALEX:** Let's talk specific numbers. How did their key franchises perform?**JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.**ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.**JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.**ALEX:** What about guidance? I imagine they had to adjust expectations.**JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit.**ALEX:** During the Q&A, there were some pointeThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)──────────# Beta Finch Podcast Script: McDonald's Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and with me as always is Jordan. Today we're diving into McDonald's Q1 2026 results, and wow, there's a lot to unpack here. Jordan, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex, and yeah - McDonald's certainly delivered some interesting headlines this quarter. On the surface, the numbers look pretty solid - global comparable sales up 3.8%, system-wide sales growing 6% in constant currency. But when you dig deeper, there are some real challenges brewing beneath those golden arches.**ALEX**: Absolutely. Let's start with the good news. The U.S. business showed resilience with 3.9% comparable sales growth, and they're gaining market share in nearly all their top 10 markets globally. That's impressive in this environment. But Jordan, what really caught my attention was CEO Chris Kempczinski's emphasis on their "3 for 3" strategy - value, marketing, and menu innovation.**JORDAN**: Right, and the value piece is particularly crucial here. They've completely revamped their McValue platform with unanimous franchisee support - that's key. We're talking about items under $3 and a new $4 breakfast meal deal. Kempczinski was pretty emphatic about this, saying "McDonald's is not going to get beat on value and affordability."**ALEX**: That's a bold statement, but they're backing it up with action. What's interesting is they're applying lessons from international markets back to the U.S. Most of their major international markets already had this dual approach - both everyday affordable items and meal bundles. France was apparently the exception, which might explain some of their struggles there.**JORDAN**: Speaking of struggles, let's talk about the elephant in the room - those U.S. company-operated store margins. CFO Ian Borden was brutally honest, calling them "not acceptable." That's pretty remarkable transparency from a major corporation.**ALEX**: It really is. And when you connect the dots, this ties into a bigger strategic question about McDonald's ownership structure. They're essentially saying some of their franchisees are running restaurants better than McDonald's corporate is running their own locations. That's... not ideal.**JORDAN**: Exactly. And it sounds like they're seriously considering refranchising more company-operated stores. Kempczinski said they're "always looking to put restaurants in the hands of the best operator," which is diplomatic corporate-speak for "we might be selling these to franchisees who can run them better."**ALEX**: Let's shift to international markets for a moment. The UK really stood out as a success story - they're on their third consecutive quarter of market share gains with mid-to-high single-digit comp growth. Jordan, what's working there?**JORDAN**: It's that same formula - they introduced something called "Meal Deal Plus" for £5.59, which gives customers more flexibility. Plus they're executing well on marketing campaigns like the "Friends" TV show promotion. Australia's another bright spot using similar tactics. But then you have France struggling, which shows this isn't automatic - you have to execute consistently.**ALEX**: And speaking of execution, they're rolling out their new beverage platform globally. Yesterday, all U.S. restaurants started offering refreshers and crafted sodas under the McCafe brand, with Red Bull-infused energy drinks coming later this year.**JORDAN**: That timing on Red Bull is interestiThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AppLovin's absolutely explosive Q1 2026 earnings call. Jordan, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex, and wow - what a quarter to analyze! AppLovin just delivered numbers that honestly feel almost too good to be true. We're talking about a company that beat guidance across every single metric while posting 59% year-over-year revenue growth. That's not a typo, folks - fifty-nine percent growth on a $1.84 billion revenue base.**ALEX**: It's absolutely mind-blowing when you think about it. Most companies this size would be thrilled with double-digit growth, and here's AppLovin growing at nearly 60%. But Jordan, what really caught my attention was the margin expansion story. They hit an 85% adjusted EBITDA margin - that's up 400 basis points from last year.**JORDAN**: The margin story is incredible, Alex. They're generating $1.56 billion in adjusted EBITDA, which represents 86% flow-through from revenue to EBITDA quarter-over-quarter. That kind of operational leverage is just extraordinary. And they're converting that into serious cash - $1.29 billion in free cash flow for the quarter.**ALEX**: Now let's talk about the elephant in the room - or should I say the rocket ship in the room. CEO Adam Foroughi spent most of his time talking about their upcoming June launch where they're opening their Axon platform to the public for the first time in 14 years. Jordan, help our listeners understand why this is such a big deal.**JORDAN**: This is potentially transformative, Alex. For over a decade, AppLovin has been a closed platform - meaning only select partners could access their advertising technology. Starting in June, any advertiser globally can sign up and start running campaigns. Foroughi called it "a major milestone" that "changes the trajectory of this company in a very meaningful way."**ALEX**: And the timing seems perfect because their consumer vertical - that's everything outside of gaming - is absolutely on fire. It grew roughly 25% from January to March alone, and April set a record month that exceeded even their peak Q4 performance. Remember, most advertising businesses see a massive drop from Q4 to Q1, but AppLovin is actually growing through that seasonal headwind.**JORDAN**: What's fascinating is how early this consumer business still is - Foroughi emphasized it's only 18 months old! Yet it's scaling at a pace that gets the management team "very excited." He shared this incredible example of an Israeli cookware company that went from $4 million in revenue to projecting $80 million, with most of their ad spend on AppLovin's platform.**ALEX**: That's the kind of success story they want to "replicate thousands of times over," as Foroughi put it. But let's not forget about gaming, which is still the foundation of everything they do. The gaming business continues to grow at these exceptional rates, and there's this interesting shift happening where games that historically only made money from in-app purchases are now testing hybrid models that include advertising.**JORDAN**: That hybrid monetization trend could be huge, Alex. Foroughi explained that when a puzzle game company realizes a cookware brand isn't their competition, they're suddenly open to showing those ads. He estimates this could unlock 10x the market opportunity for developers because instead of monetizing just the small percentage of users who make purchases, they can now monetize their entire audience through advertising.**ALEX**: The Q&A session revealed some really interestingThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────# Beta Finch Podcast Script - Uber Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex.**JORDAN:** And I'm Jordan. Today we're breaking down Uber's Q1 2026 earnings, and wow - this was a quarter that really showed the breadth of what Uber has become.**ALEX:** Absolutely, Jordan. And before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. Now, let's get into these numbers because they were genuinely impressive. Uber delivered 21% year-over-year growth in gross bookings - that's the total value of all transactions on their platform.**ALEX:** And what I love about this quarter is how balanced the growth was. Mobility hit 20% growth with record margins, Delivery grew 23% driven by grocery and retail, and here's the kicker - Freight returned to growth for the first time in nearly two years.**JORDAN:** That Freight turnaround is huge, Alex. That's been a drag on their numbers for a while. But the real standout for me was the profitability story. Non-GAAP earnings per share jumped 44% year-over-year - that's more than twice as fast as their bookings growth.**ALEX:** Exactly! And they returned a record $3 billion to shareholders through buybacks this quarter. But let's talk about some of the strategic milestones because there were some big ones.**JORDAN:** Oh absolutely. They crossed 50 million Uber One members - that's their subscription service - and hit 10 million drivers and couriers globally. CEO Dara Khosrowshahi mentioned that Uber One members now account for over 50% of their total bookings and spend three times more than non-members.**ALEX:** That subscription moat is becoming really powerful. They added 20 million Uber One members in just one year, going from 30 million to 50 million. And speaking of strategic moves, they made some big announcements at their GO-GET event.**JORDAN:** Right - they're expanding into hotel bookings through a partnership with Expedia, adding 700,000 hotels to the platform. It's a classic Uber move - they're already huge in airport trips, which represent about 15% of their mobility bookings, so hotels are a natural extension.**ALEX:** And the numbers support this strategy. Khosrowshahi mentioned that 40% of US riders take trips outside their home city, and globally they had over 1.5 billion trips happening outside users' home cities last year. That's a massive travel audience to tap into.**JORDAN:** But let's talk about what's really driving growth in their core business - insurance cost savings. This is huge for their US operations, Alex.**ALEX:** Absolutely. CFO Balaji Krishnamurthy said they expect hundreds of millions in insurance savings this year. And here's the key - they're passing those savings back to consumers through lower prices, which is driving trip acceleration, especially in California markets like LA and San Francisco.**JORDAN:** The elasticity story is working. Lower prices are translating directly to more trips, and LA - which had the biggest insurance headwinds over recent years - is now seeing significantly better growth trends than the rest of California and the country.**ALEX:** Now, we have to talk about autonomous vehicles because that dominated a lot of the Q&A session. They have over 30 AV partners now and their autonomous mobility trips grew more than 10x year-over-year.**JORDAN:** And they're on track to be live in up to 15 cities by year-end. But what's interesting is how they're positioning this not as a threat to their driver network, but as expanding the entire market. Khosrowshahi pointed out that in San Francisco and LA, whereThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: ENERGY (https://betafinch.com/groups/ENERGY)──────────**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into EOG Resources' first quarter 2026 earnings call. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks, Alex. And wow, what a quarter for EOG! They're definitely benefiting from some major geopolitical tailwinds, but there's a lot more substance here than just riding the oil price wave.**ALEX:** Absolutely. Let's start with the numbers because they're pretty impressive. EOG generated $1.8 billion in adjusted net income and $1.5 billion in free cash flow for the quarter. They returned nearly $950 million to shareholders through dividends and buybacks. Jordan, what jumped out at you?**JORDAN:** The cash flow generation is remarkable, especially when you consider they're projecting a record $8.5 billion in free cash flow for the full year 2026. But here's what I found fascinating - they're maintaining their $6.5 billion capital budget while increasing oil production guidance by 2,000 barrels per day and NGL production by 6,000 barrels per day. That's capital discipline in action.**ALEX:** That's a great point about capital discipline. They're essentially reallocating capital from natural gas assets to oil-weighted assets within the same budget. CEO Ezra Yacob was pretty clear about this being a response to current market dynamics - oil prices surging due to the Iran conflict while natural gas prices remain soft.**JORDAN:** Right, and let's talk about that geopolitical situation because it's driving a lot of their strategy. The conflict has removed an estimated 900 million barrels from global markets through June 2026, and EOG's management seems to believe this sets up a higher oil price floor going forward, even after the conflict resolves.**ALEX:** The international expansion story is interesting too. They've got operations starting up in both the UAE and Bahrain. During the Q&A, management mentioned they're seeing strong partnerships with ADNOC and BAPCO, and they expect initial results from these exploration programs in the second half of 2026.**JORDAN:** And their marketing strategy is really paying dividends - literally. They have 250,000 barrels per day of export capacity out of Corpus Christi, which gives them flexibility to price crude domestically or link to Brent pricing. Plus, their Cheniere LNG contract is expanding to 420,000 BTUs per day, with pricing linked to either JKM or Henry Hub at their election.**ALEX:** That pricing flexibility is huge in volatile markets. CFO Ann Janssen mentioned they've been able to sell multiple cargoes at attractive pricing thanks to that export capacity. It's like having optionality built into their business model.**JORDAN:** Speaking of Ann Janssen, let's talk shareholder returns because this is where things get really interesting. They're committed to returning at least 70% of free cash flow this year, which would be a record. And they've been aggressive on buybacks - 3.2 million shares in Q1, plus another 2.3 million shares just in April.**ALEX:** The buyback strategy seems pretty opportunistic. During the Q&A, there was this great exchange about being tactical versus having a ratable program throughout the year. Management seems confident they're finding value in their own stock, even with oil prices elevated.**JORDAN:** What I found telling was CEO Yacob's comment about potentially building some cash on the balance sheet during this upcycle to prepare for countercyclical investments when prices eventually pull back. That's exactly what they did with acquisitions like EncinoThis episode includes AI-generated content.

More earnings analysis: https://betafinch.com──────────ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what matters most from corporate earnings calls. I'm Alex, and joining me as always is my co-host Jordan.JORDAN: Hey everyone! Today we're diving into Disney's Q2 2026 earnings call, and wow - this was Josh D'Amaro's first call as CEO, so there was a lot to unpack.ALEX: Absolutely. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Right, so let's get into the numbers first. Disney posted solid results - revenue grew 7%, total segment operating income up 4%. They actually outperformed their own guidance for the quarter, which is always nice to see.ALEX: Yeah, and what really caught my attention was the streaming business. Disney+ revenue growth actually accelerated from 11% in Q1 to 13% in Q2. That's the opposite of what we're seeing from some other streaming players who are hitting growth walls.JORDAN: Exactly! And it wasn't just subscriber volume driving that growth - it was both rate increases AND more subscribers. Plus they had double-digit advertising revenue growth. The integrated Disney+ and Hulu experience seems to be helping with retention too.ALEX: Now, the parks business - Disney Experiences - that was interesting. Revenue up 7%, operating income up 5%, but there were some headwinds. Jordan, can you break down what's happening there?JORDAN: Sure. So they're dealing with two main challenges: reduced international visitation to US parks, and the impact of Universal's Epic Universe opening, which is pulling some attendance away. Domestic park attendance was actually down 1% in the quarter. But here's the key - Hugh Johnston, the CFO, said they expect these headwinds to ease in the back half of the year as they lap these impacts.ALEX: And they're still investing heavily in growth. They just opened World of Frozen at Disneyland Paris and launched the Disney Adventure cruise ship in Asia. D'Amaro mentioned they have more projects underway globally than at any time in Disney's history.JORDAN: That ambitious expansion is really part of D'Amaro's bigger vision. He kept talking about Disney+ becoming the "digital centerpiece" of the company - not just a streaming service, but a hub that connects everything Disney does.ALEX: Right, and this is where it gets really interesting from a strategic standpoint. D'Amaro is talking about creating a more connected Disney experience across streaming, sports, games, and physical experiences. Think about it - someone watches a Disney movie, then visits a theme park, buys merchandise, plays games - each touchpoint reinforces the others.JORDAN: It's all about lifetime value. He specifically mentioned that their biggest opportunity might be reducing churn on Disney+. If they can keep subscribers engaged longer, that flows through to everything else.ALEX: The technology piece was fascinating too. They're going heavy on AI across multiple areas - hyper-personalized recommendations, better ad targeting, even precision labor forecasting at the theme parks to optimize staffing.JORDAN: And they're experimenting with short-form content and vertical video to meet younger audiences where they are. D'Amaro specifically called out Gen Alpha as important for Disney's future.ALEX: Now, one thing that came up multiple times in the Q&A was about Disney's portfolio - specifically whether they'd consider selling off some assets. Hugh Johnston was pretty clear that they view their entertainment networks as "brands with studios" rather than just distribution platforms, and separating them would be complex without creating much value.JORDAN: Yeah, and on ESPN, they'reThis episode includes AI-generated content.

More earnings analysis: https://betafinch.comGroups: CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)──────────**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the quarterly reports so you don't have to. I'm Alex, and joining me as always is Jordan. Today we're diving into AMD's absolutely stellar Q1 2026 results that had Wall Street buzzing.But before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Jordan, AMD just dropped some seriously impressive numbers. Walk us through the headline figures.**JORDAN:** Alex, these results were nothing short of spectacular. AMD crushed expectations with $10.3 billion in revenue - that's 38% growth year-over-year. But here's the kicker - they're guiding for $11.2 billion in Q2, which would be 46% year-over-year growth. Their data center business is absolutely on fire, hitting a record $5.8 billion, up 57% from last year.**ALEX:** And the profitability story is even better, right? I saw some incredible cash flow numbers.**JORDAN:** Exactly! Free cash flow more than tripled to a record $2.6 billion - that's 25% of revenue. Earnings per share jumped 43% to $1.37. Lisa Su called it "a clear inflection in our growth trajectory and a structural shift in our business." Data center is now their primary growth driver, which is a massive change from just a few years ago.**ALEX:** Now, the really interesting story here seems to be what AMD is calling the "Agentic AI" revolution. Jordan, they literally doubled their server CPU market size projection in just six months. How does that happen?**JORDAN:** It's pretty remarkable, Alex. Back in November at their analyst day, they projected the server CPU market would grow at about 18% annually to around $60 billion by 2030. Now they're saying it'll grow at over 35% annually, reaching more than $120 billion by 2030. Lisa Su explained it perfectly - as AI adoption scales and you get more inference workloads and AI agents, you need dramatically more CPU compute for orchestration, data processing, and managing these AI workloads. It's not just about the GPUs anymore.**ALEX:** And AMD is positioned perfectly for this, aren't they? They're seeing massive growth in both their server CPUs and their AI accelerators.**JORDAN:** Absolutely. Their EPYC server CPU business grew over 50% year-over-year, and they're guiding for over 70% growth in Q2. They're gaining market share against Intel while also benefiting from this expanding market. Plus, they landed some massive AI partnerships - they announced deals with Meta for up to 6 gigawatts of AMD Instinct GPUs and expanded their OpenAI partnership.**ALEX:** Six gigawatts? That's... that's a lot of computing power. Put that in perspective for our listeners.**JORDAN:** To put it simply, that's enough power to run a small city! These are multi-year, multi-billion dollar commitments. AMD is becoming a core infrastructure partner for the world's biggest AI companies. And the exciting part is Lisa Su mentioned they're seeing demand forecasts exceeding their initial plans, with visibility all the way down to which specific data centers these chips are going into.**ALEX:** Now, it wasn't all perfect news. There were some headwinds mentioned, particularly around memory costs and China. Can you break that down?**JORDAN:** Right, so memory prices are inflating across the industry, which is impacting both costs and consumer demand. AMD expects this to hurt PC and gaming demand in the second half of the year. They also saw their AI GPU revenue decline slightly in Q1 due to lower China sales, though that's more of a geographic mix shift than a fundamenThis episode includes AI-generated content.

# Beta Finch Podcast Script: Pfizer Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking Pfizer's Q1 2026 earnings call, and folks, there's quite a bit to unpack here.Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And what a quarter this was for Pfizer! They really came out swinging with some impressive numbers and some game-changing legal developments. Should we start with the headline figures?**ALEX:** Absolutely. Pfizer reported Q1 revenues of $14.5 billion, which actually exceeded their own expectations. That's a 2% operational increase overall, but here's the kicker - if you strip out their COVID products, the underlying business grew about 7% operationally. That's solid growth in a challenging environment.**JORDAN:** And the earnings story is even better. They hit $0.75 in adjusted diluted earnings per share, again beating expectations. What really caught my attention though was their launched and acquired products - these grew 22% operationally to $3.1 billion in the quarter. That's the portfolio transformation strategy Albert Bourla has been talking about really starting to pay off.**ALEX:** Speaking of transformative developments, we need to talk about the elephant in the room - or should I say, the legal victories in the room. Pfizer had two major legal wins that could reshape their entire growth trajectory post-2028.**JORDAN:** Right, the Vyndamax patent settlement is huge. This drug, which treats a rare heart condition, was facing generic competition, but now Pfizer has extended exclusivity until mid-2031. We're talking about a $6 billion-plus product here, Alex. CEO Albert Bourla said this "has the potential to change the growth profile of the company significantly post-2028."**ALEX:** And then there's the Belgian court ruling on their Comirnaty contracts with EU countries. CFO Dave Denton called this "a positive for future EPS and cash flow." These aren't just minor legal technicalities - these are major financial game-changers that give Pfizer much clearer visibility into their cash flows.**JORDAN:** Which brings us to one of the most interesting parts of the call - Pfizer's new confidence about their post-2028 growth trajectory. Bourla said they now expect a "5-year period of high single-digit revenue CAGR" starting in 2029. That's a pretty bold statement, especially when you consider they're still navigating some significant patent cliff challenges.**ALEX:** Let's break that down for listeners. CAGR stands for Compound Annual Growth Rate. So Pfizer is essentially saying that starting in 2029, they expect to grow revenues at a high single-digit percentage rate - so probably 7-9% annually - for five straight years. That would be impressive for any pharma company, let alone one coming off the COVID revenue peaks.**JORDAN:** And the foundation for that confidence seems to be their pipeline and their recent acquisitions. They mentioned having about 20 pivotal study starts planned this year, 8 key data readouts, and 4 regulatory decisions. That's a packed R&D calendar. They're particularly excited about their oncology portfolio, especially after the Seagen acquisition.**ALEX:** The oncology story is fascinating. They reported 20% year-over-year growth in their Seagen products, and they've got some potentially blockbuster readouts coming. There's Padcev for bladder cancer, which affects over 600,000 patients globally, and their multiple myeloma drug Elrexfio just hit positive Phase III results.**JORDAN:** Don't forget about the obesity play with their Metsera acquisition.This episode includes AI-generated content.

**Beta Finch Podcast Script: Duke Energy Q1 2026 Earnings**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear insights. I'm Alex, and with me as always is Jordan. Today we're diving into Duke Energy's first quarter 2026 results, and folks, this utility giant is making some serious moves in the data center boom.Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And wow, what a quarter for Duke Energy! They posted adjusted earnings per share of $1.93, beating last year's $1.76. But honestly, the earnings beat is just the appetizer here - the main course is this massive data center story that's unfolding.**ALEX:** Absolutely right, Jordan. Duke is sitting at the epicenter of this AI infrastructure buildout. They've now secured 7.6 gigawatts of electric service agreements with data centers - that's adding another 2.7 gigawatts just this quarter alone. To put that in perspective, we're talking about enough power for millions of homes.**JORDAN:** And what I love about Duke's approach here is how they're protecting existing customers. CEO Harry Sideris really emphasized this - these new data center contracts include minimum demand provisions, credit support, refundable capital advances, and termination charges. Basically, if these big tech companies want Duke's power, they're paying their fair share upfront.**ALEX:** That's crucial because one of the biggest concerns investors have had about this data center boom is whether utilities will stick existing customers with the bill for all this new infrastructure. Duke seems to have that covered. In fact, they're saying these incremental volumes will actually benefit all customers over time as system costs get spread over a larger base.**JORDAN:** Speaking of customer benefits, Alex, did you catch those two major announcements that total over $5 billion in customer savings? First, they struck a multi-year deal to monetize up to $3.1 billion in clean energy tax credits through 2028, with proceeds flowing back to customers. And second, they got regulatory approval to combine their two Carolina utilities, which should save customers $2.3 billion through 2040.**ALEX:** Those are massive numbers, Jordan. And the timing is perfect because Duke has rate cases pending in the Carolinas right now. CFO Brian Savoy mentioned they might use some of these savings as tools to mitigate rate increases. Smart move - it shows regulators they're serious about keeping rates affordable even as they invest heavily in new infrastructure.**JORDAN:** Let's talk about that infrastructure investment because it's staggering. Duke is executing a $103 billion capital plan - that's with a "B" - and they're funding it through these strategic asset sales. They closed $2.8 billion from selling a minority stake in their Florida utility to Brookfield, plus another $2.5 billion from selling their Tennessee gas business to Spire.**ALEX:** Over $5 billion in proceeds that strengthen their balance sheet while funding growth. And they're not just building for data centers - they're adding 14 gigawatts of generation over the next five years. A big chunk of that is natural gas plants, including a 1.4 gigawatt facility in South Carolina that just got approved.**JORDAN:** The nuclear angle is interesting too, Alex. Duke operates the largest regulated nuclear fleet in the nation, and they just got approval to extend the life of their Robinson Nuclear Plant. That's their second plant to reach this milestone, and they plan to seek similar extensions for all their remaining reactors. Nuclear provides about $600 million in annual tax credits to customers, so keeping these planThis episode includes AI-generated content.

**Beta Finch Podcast Script**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex Pharmaceuticals' Q1 2026 earnings call - and wow, Jordan, this was packed with updates.JORDAN: Absolutely, Alex. But before we jump in, let me get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Thanks, Jordan. Now, let's talk Vertex. This biotech giant just delivered some impressive numbers - $2.99 billion in total revenue for Q1, representing 8% growth year-over-year. But what really caught my attention was how they're diversifying beyond their cystic fibrosis cash cow.JORDAN: Right, and that diversification story is really the headline here. CEO Reshma Kewalramani emphasized that their newer products - KASJEVY and GERNAVICS - drove about 25% of their total revenue growth. That's a company successfully expanding its footprint beyond a single therapeutic area.ALEX: Let's break down those newer products. KASJEVY, their gene editing therapy, brought in $43 million in Q1 revenue with over 500 patients now having started treatment. Then there's GERNAVICS for pain management at $29 million in revenue. But the real excitement seems to be around their renal pipeline, particularly something called Povitacicept or "Povi."JORDAN: Oh, the Povi data was genuinely impressive, Alex. They just completed what Kewalramani called their fastest regulatory submission in company history - 27 days from database lock to filing. The Phase III interim results for IgA nephropathy showed a 52% reduction in proteinuria, which is a key marker doctors watch. Kewalramani described the results as "sparkling from top to bottom."ALEX: And they're not stopping there with renal disease. They're positioning this as potentially their fourth major franchise alongside CF, blood disorders, and pain. The addressable patient population across their renal programs could be in the hundreds of thousands when you add up all the different kidney diseases they're targeting.JORDAN: What I found interesting in the Q&A was when analyst Jessica Fye asked about renal potentially rivaling their CF business in size. Kewalramani didn't shy away from that comparison. She pointed out that while each kidney disease is rare, they're "common rare diseases" - IgA nephropathy alone affects about 150,000 patients in North America and Europe.ALEX: The numbers definitely support the growth story. Non-GAAP earnings per share came in at $4.47, up from $4.06 the previous year. They're managing expenses well while investing heavily in these new areas - SG&A expenses were up 30% year-over-year, but that's driven by commercial investments in pain and renal programs.JORDAN: Speaking of investments, they spent about $344 million buying back shares in Q1, showing they're returning cash to shareholders while still funding growth. They ended the quarter with $13 billion in cash and investments, so they've got plenty of firepower.ALEX: Now, it wasn't all good news. They had to discontinue their VX-522 program for CF patients who can't benefit from their current modulators. Kewalramani explained they couldn't overcome tolerability issues related to lung inflammation, likely from the delivery mechanism.JORDAN: That's about 5,000 patients who still can't be helped by Vertex's current CF portfolio. But Kewalramani was adamant they're not giving up on this population. She said their "commitment to CF is absolute and steadfast" and they'll go back to the drawing board on delivery methods.ALEX: Let's talk guidance. They're sticking with their full-year revenue guidance of $12.95 to $13.10 billion, repreThis episode includes AI-generated content.

# Beta Finch Podcast Script: Palantir Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is Jordan. Today we're diving into Palantir's absolutely explosive Q1 2026 results - and folks, when I say explosive, I mean it. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Alex, I've been covering earnings for years, and these Palantir numbers are just wild. We're talking about 85% year-over-year revenue growth - their highest as a public company. But what really caught my eye was their U.S. business hitting triple digits for the first time since their direct listing.**ALEX:** Right, 104% growth in the U.S.! And get this - their U.S. business now represents 79% of total revenue. They pulled in $1.63 billion in revenue for the quarter, up 16% sequentially. But Jordan, what's your take on their "Rule of 40" score hitting 145?**JORDAN:** For listeners who might not know, the Rule of 40 combines revenue growth rate and profit margins - and anything over 40 is considered excellent. Palantir just scored 145, up from 127 last quarter. That's not just good, that's almost unheard of at this scale.**ALEX:** And they're not slowing down. They raised their full-year 2026 revenue guidance to $7.656 billion - that's 71% growth year-over-year and a 10% bump from their previous guidance. What's driving all this growth?**JORDAN:** It's all about their AIP platform - their Artificial Intelligence Platform. CEO Alex Karp was pretty bold on the call, claiming "almost every single highlighted example of AI that actually is producing results in the U.S. is actually Palantir." That's a huge statement, but the numbers seem to back it up.**ALEX:** Speaking of bold statements, Karp mentioned they're achieving this growth with essentially just seven salespeople who actually sell, compared to what would normally be 7,000 for a company their size. That suggests incredible product-market fit.**JORDAN:** The enterprise AI story is fascinating here. While everyone's talking about AI "slop" - their term for unreliable AI outputs - Palantir positions their platform as the "no-slop zone." They're saying enterprises need precision and governance when deploying AI, not just flashy demos.**ALEX:** Let's break down the segments. Their commercial business grew 95% year-over-year to $774 million, with U.S. commercial specifically up 133%. But government wasn't slouch either - up 76% to $858 million.**JORDAN:** The government wins are particularly interesting. They landed a $300 million USDA contract and their Maven Smart System for defense continues expanding. Ryan Taylor mentioned that Maven usage has doubled in the past four months and is now 4x what it was twelve months ago.**ALEX:** What struck me was their customer expansion. Net dollar retention hit 150% - that means existing customers are spending 50% more than they were a year ago. And they're now at 1,007 total customers, up 31% year-over-year.**JORDAN:** The cash generation is incredible too. They generated $899 million in cash from operations and $925 million in adjusted free cash flow. Karp made a great point - their free cash flow this quarter is larger than their total revenue was in the same quarter last year.**ALEX:** During the Q&A, there were some interesting exchanges about competition from AI labs like OpenAI and Anthropic moving into enterprise. How did management respond to that?**JORDAN:** Karp was pretty dismissive, honestly. He basically said "go ahead and try the alternatives" - test out what he calls the "slop" and then compare it to what Palantir delivers. He seems confident that enterprises doing real-world testing will come back to Palantir.**ALEX:** CTO Shyam Sankar made a fascinatinThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Exxon Mobil's Q1 2026 earnings call - and wow, what a quarter to unpack. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And right off the bat, we need to address the elephant in the room - this earnings call was dominated by the ongoing Middle East conflict and its impact on global energy markets. CEO Darren Woods opened with some pretty sobering commentary about the situation.**ALEX**: Absolutely. Woods was very direct about the human cost first, mentioning their colleagues and partners living under daily threats in the region. But from a business perspective, Jordan, the disruption has actually highlighted Exxon's competitive advantages in a major way.**JORDAN**: Exactly. What struck me was how Woods framed this as essentially a stress test for all the changes they've made over the past decade. And by most measures, they seem to have passed with flying colors. Despite what he called "unprecedented disruption in the world supply of oil and natural gas," they maintained deliveries globally and even ramped up refining production by 200,000 barrels per day from February to March.**ALEX**: That's like adding a mid-sized refinery overnight! And the financial results reflect this operational excellence. Even excluding timing effects and identified items, their first-quarter earnings per share were up versus 2025. CFO Kathy Mikells highlighted that their Energy Products segment made $2.8 billion in the quarter - that's up $2 billion from last year.**JORDAN**: The refining story is particularly compelling. Remember when Exxon announced that Beaumont refinery expansion back in 2023? There were lots of questions about whether refining investments made sense. Well, Woods announced that expansion has already fully recovered its initial investment - ahead of expectations.**ALEX**: And they're not just benefiting from higher margins - they're creating structural advantages. Their Gulf Coast refineries ran at record utilization rates, and they've got this global supply chain organization that rapidly executed alternate routings from the US Gulf Coast to Asia. It's that scale and integration advantage Woods keeps talking about.**JORDAN**: Speaking of scale advantages, let's talk about their growth engines. In Guyana, they hit record production levels again and have three new projects under construction. The Oahu project expects first oil late this year. But what I found interesting was their $100 million commitment over ten years for STEM education in Guyana - that's the kind of long-term relationship building that creates sustainable competitive advantages.**ALEX**: And in the Permian, they're still on track for 1.8 million oil-equivalent barrels this year, with that longer-term target of 2.5 million. What's interesting is Woods' confidence that they're not seeing any plateau in opportunities there, unlike some competitors who've predicted resource constraints.**JORDAN**: The LNG story is fascinating too. Golden Pass achieved first LNG in March - that's about a 5% increase in US LNG exports. And by the time all three trains are online, they'll increase current US exports by roughly 15%. But here's what's really notable - with the Middle East disruptions, that "long" LNG market everyone was predicting has essentially disappeared overnight.**ALEX**: Right, and they've got Papua New Guinea and Mozambique LNG projects expecting final investment decisions later this year. Woods was pretty confident about their positioning in what's now a much tighter LNG market.**JORDAN**: Let's dive into some of the Q&A highlights, becauseThis episode includes AI-generated content.

# Beta Finch Podcast Script - Linde Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and joining me as always is Jordan. Today we're unpacking Linde's Q1 2026 results - the industrial gas giant that just delivered another solid quarter despite some serious global headwinds.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And wow, what a quarter to analyze. Linde really showed why they're considered the gold standard in industrial gases. EPS of $4.33 was up 10% year-over-year, with operating margins hitting that impressive 30% mark. When you've got geopolitical chaos, supply chain disruptions, and economic uncertainty swirling around, delivering those kinds of numbers is no small feat.**ALEX:** Absolutely. And let's talk about that revenue picture - $8.8 billion in sales, up 8% year-over-year. But here's what I found interesting, Jordan: when you strip out the 5% currency tailwind and 1% from acquisitions, underlying sales growth was a more modest 3%. That tells us the real story is about pricing discipline rather than volume explosions.**JORDAN:** Exactly right, Alex. CEO Matthew White was pretty clear about this during the call - they're seeing 2% higher pricing and just 1% volume growth. And when you dig into the geographic breakdown, it's really a tale of three regions. The Americas are firing on all cylinders with base volume growth, APAC is holding steady thanks to project startups, but EMEA? That's where the weakness is concentrated.**ALEX:** The EMEA situation is fascinating from a macro perspective. White mentioned they're seeing production shifting away from Continental Europe to more feedstock-advantaged assets in the Americas. He basically said if your feedstock comes on a ship, you're in trouble right now, but if it's pipeline or rail-based, you're in a better position.**JORDAN:** And that brings us to one of the most interesting parts of this call - helium. I mean, who would have thought helium would be such a hot topic on an earnings call? But with the Middle East conflict disrupting supply chains, Linde is sitting pretty with their diversified sourcing. They're about 85-90% contracted on helium, and White said they're already securing new long-term agreements rather than chasing spot market gains.**ALEX:** Smart strategy there. But let's talk about the real growth engine everyone's buzzing about - commercial space. This is where it gets exciting, Jordan. Linde mentioned they're investing over $1 billion in ultra-high-purity plants for advanced semiconductor fabs, and the space business is growing so fast they might break it out as a separate segment when it hits 5% of sales.**JORDAN:** The math on that is pretty striking, Alex. Five percent of sales would be about $1.7 billion annually. White mentioned they previously thought space might hit $1 billion by decade's end, but now they're talking about potentially reaching $1.7 billion. That's not just growth - that's explosive growth in a completely new market.**ALEX:** And the drivers make sense. It's all about launch frequency, rocket size, and propellant type. Linde supplies oxygen for oxidizer and nitrogen for densification, plus hydrogen for hydrogen-fueled rockets. With companies racing to build satellite constellations and the entire commercial space economy taking off, Linde is positioned right in the sweet spot.**JORDAN:** Now let's address the elephant in the room - guidance. For Q2, they're guiding $4.40 to $4.50 EPS, which is 8-10% growth. Full year guidance is $17.60 to $17.90, representing 7-9% growth. Here's what I find notable: they raised the bottom of the range by 20 centThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Chevron's Q1 2026 earnings call. Now, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And what a quarter to analyze! Chevron just reported some really solid numbers despite operating in what can only be described as a pretty chaotic global environment.**ALEX:** Absolutely. Let's start with the headline numbers. Chevron posted $2.2 billion in earnings, or $1.11 per share. But the adjusted earnings tell a cleaner story - $2.8 billion or $1.41 per share. Jordan, what stood out to you in these results?**JORDAN:** Well, the big story here is how Chevron's integrated model really shined during market volatility. They had about $3 billion in unfavorable timing effects due to steep commodity price rises in March, but management was clear this was largely paper positions that would unwind. What's impressive is how they navigated supply disruptions.**ALEX:** Right, and CEO Michael Wirth really emphasized this integration advantage. They're now running over 40% equity crude in their Asian refineries - compared to their historical 15% across the system. That's a massive operational shift.**JORDAN:** Exactly. In the U.S., they're above 50% equity crude throughput at some refineries. This isn't just about margins - it's about supply security. When global energy markets are tight, having your own crude to feed your own refineries is like having a strategic ace up your sleeve.**ALEX:** Let's talk about the geopolitical elephant in the room. There's clearly some major conflict affecting Middle Eastern energy supplies, though the transcript doesn't specify exactly what. How is Chevron positioned?**JORDAN:** Interestingly, Chevron seems relatively insulated. Less than 5% of their portfolio is in the Middle East region. But they're definitely benefiting from the market dynamics. Their Australian LNG facilities are running at full capacity, and they just sold their first U.S. LNG cargo into Europe - talk about good timing.**ALEX:** And the production numbers are strong across the board. They're reaffirming 7-10% production growth for the year, with U.S. production over 2 million barrels per day. The TCO project in Kazakhstan is back above 1 million barrels per day after some earlier disruptions.**JORDAN:** What I found fascinating was the Venezuela update. They've expanded their position there through an asset swap with PDVSA, increasing their stake in Petro Independencia to 49%. But Wirth was clear - they're still in "debt recovery mode" and expect Venezuela to represent just 1-2% of cash flow from operations.**ALEX:** The Q&A session had some really telling moments. When analysts pressed about capital allocation in this higher price environment, CFO Eimear Bonner was adamant about staying disciplined. No changes to their $2.5-3 billion quarterly buyback range.**JORDAN:** That's smart. She said it's too early - only eight weeks into the conflict - to fundamentally change their outlook. They're not being pro-cyclical on buybacks, which shows real capital discipline.**ALEX:** One of the more intriguing discussions was about their exclusive negotiations with Microsoft for power projects. Wirth mentioned they're advancing a West Texas project and could reach FID later this year. That's Chevron diversifying into the data center power space.**JORDAN:** The timing there is interesting too. With AI driving massive power demand and Microsoft being their cloud provider, this feels like a natural partnership. Wirth seemed confident they could align Microsoft's power price expectations with Chevron'sThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT****ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest quarterly results and what they mean for investors. I'm Alex.**JORDAN**: And I'm Jordan. Today we're breaking down Colgate-Palmolive's Q1 2026 earnings call, and there's quite a bit to unpack here.**ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. Now, Alex, Colgate had an interesting quarter - some really strong performance in certain areas, but they're also dealing with significant headwinds. Where do you want to start?**ALEX**: Let's kick off with the headline numbers. Colgate delivered what CEO Noel Wallace called "strong top and bottom line growth" with organic sales growth actually accelerating from Q4. They saw growth in both volume and pricing across all four categories and four of five divisions, which is pretty impressive breadth.**JORDAN**: That's right, and what really caught my attention was the geographic mix. Emerging markets were the star of the show, particularly Asia Pacific. Wallace mentioned that these are regions where Colgate's global brands have higher market shares and greater scale advantages, so they're doubling down on investments there.**ALEX**: Speaking of investments, they're maintaining their focus on brand equity and advertising spending, which is notable given the cost pressures they're facing. But Jordan, let's talk about the elephant in the room - that $300 million increase in expected raw material and logistics costs.**JORDAN**: Yeah, this is where things get interesting from a margins perspective. They had to revise their gross margin outlook downward because of these cost pressures. CFO Stanley Sutula broke it down - about two-thirds of that $300 million hit is from raw materials, one-third from logistics. The big culprits? Oil byproducts like resins and petrochemicals, with spending in those areas expected to be up more than 20% year-over-year.**ALEX**: And they're assuming crude oil at around $110 for their planning purposes. But here's what I found encouraging - despite these headwinds, they reaffirmed their full-year guidance for both top and bottom line growth. How are they managing to do that?**JORDAN**: It comes down to what Wallace calls their "flexible P&L model." They're offsetting these cost pressures through several levers: revenue growth management, or RGM, productivity initiatives, and they just announced an acceleration of their Strategic Growth and Productivity Program - or SGPP.**ALEX**: Let's dig into that SGPP announcement because it's pretty significant. They're now targeting $200 million to $300 million in annualized savings, with most of those savings hitting in 2027 and 2028. Wallace emphasized this isn't an extension of the program - it's still completing by end of 2028 - but they've identified additional opportunities.**JORDAN**: Right, and Sutula explained that the strong execution from their teams allowed them to reach the high end of their initial targets, plus they found new ways to simplify operations and enhance efficiency. I like that they're being proactive about organizational structure and reducing complexity.**ALEX**: Now, the regional performance was really telling. Asia Pacific was a standout, with improvements in both China through their Hawley & Hazel business and strong performance in India. Wallace mentioned they're not "completely out of the woods" in China yet, but the interventions they've made - accelerated innovation, better omnichannel execution - are starting to pay off.**JORDAN**: Latin America also had another strong volume quarter with mid-single-digit growth. Wallace was particularly enthusiastThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is my co-host Jordan. Today we're diving into Cigna Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including some major leadership changes and strategic pivots.But before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Thanks Alex. And speaking of major changes, this earnings call was pretty historic - it was CEO David Cordani's final quarterly call after 17 years leading the company. But the numbers certainly gave him a strong send-off.ALEX: Absolutely! So let's start with the headline numbers. Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79. That EPS represents 16% year-over-year growth, which is pretty impressive. And based on this strong performance, they raised their full-year 2026 EPS guidance to at least $30.35.JORDAN: What's interesting is that both of their main segments - Evernorth and Cigna Healthcare - performed above internal expectations. Evernorth earnings were slightly ahead, while Cigna Healthcare really exceeded expectations with 18% earnings growth year-over-year. The medical care ratio came in at 79.8%, which was better than their guidance of slightly below 81%.ALEX: Now Jordan, there were some significant strategic announcements that I think investors need to pay attention to. Can you walk us through those?JORDAN: Sure thing. Cigna made two big portfolio moves. First, they're planning to exit the individual exchange business at the end of 2026. This isn't a huge surprise - it's been a small and shrinking business for them. CEO-elect Brian Evanko said they couldn't see a clear path to scale it meaningfully within Cigna's overall size.The second move is potentially bigger - they announced a strategic review for eviCore, which handles prior authorization services for multiple health plans. This seems to be driven by the industry's progress on standardizing and automating prior authorization processes.ALEX: And these moves really fit into their broader strategy of portfolio shaping, right? They're focusing resources on their three core growth platforms.JORDAN: Exactly. Evanko outlined those three platforms clearly: Specialty and Care Services, which represents about 35% of company income and is growing 8-12% annually; Pharmacy Benefit Services at about 25% of income; and Cigna Healthcare at 40% of income. They're essentially doubling down on what's working and shedding what isn't.ALEX: Let's talk about that specialty business because it really shone this quarter. Specialty and Care Services earnings grew 20% to $1.1 billion. What's driving that?JORDAN: Three main factors. First, solid specialty volume growth across the board. Second - and this is interesting - continued adoption of biosimilars and specialty generics. These deliver savings to patients while actually improving margins for Cigna. Third, they're getting contributions from their investment in Shields Health Solutions, which they made late last year.David Cordani specifically highlighted how they're using AI to improve biosimilar conversions. For drugs like Humira and Stelara, they're offering $0 out-of-pocket costs to patients while using AI to identify personalized conversion strategies. It's a win-win - lower costs, higher patient satisfaction, and better margins.ALEX: That ties into something Brian Evanko emphasized about the future - this focus on AI and data analytics. He's clearly putting his stamp on the company's direction.JORDAN: Right. When he takes over as CEO in July, Evanko outlined three areas of intensification: better use of data and AI for personalized care, drivinThis episode includes AI-generated content.

**Beta Finch Podcast Script - Stryker Q1 2026 Earnings**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into Stryker's Q1 2026 results, and wow, this was definitely not your typical earnings call.**ALEX:** Before we get into it, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. So Alex, let's start with the elephant in the room - Stryker got hit by a cyberattack late in Q1. How bad was the damage?**ALEX:** It was significant, Jordan. Organic sales growth came in at just 2.4% - way below what you'd normally expect from Stryker. Even more telling, adjusted earnings per share dropped 8.5% to $2.60. CEO Kevin Lobo mentioned they had 40,000 laptops wiped and were essentially shut down for about three weeks.**JORDAN:** That's brutal. But here's what caught my attention - despite all this chaos, they maintained their full-year guidance. That's either incredibly optimistic or they have serious confidence in their recovery plan.**ALEX:** I'm leaning toward confidence. CFO Preston Wells was pretty detailed about why they think they'll bounce back. He explained that different business units were affected differently based on their operating models. For example, their orthopedic business has a lot of consigned inventory sitting right at hospitals, so surgeries could continue even when Stryker's systems were down.**JORDAN:** Right, it was more of a revenue recognition issue there rather than lost procedures. But their capital equipment business - things like hospital beds and defibrillators - that's where they really got hit because those are made-to-order products.**ALEX:** Exactly. And Wells said most of that lost production will shift to Q3 and Q4 rather than Q2, which makes sense given manufacturing lead times. What I found interesting was how resilient their underlying business seems to be.**JORDAN:** Talk about that resilience - what are the bright spots?**ALEX:** Well, they had their best-ever Q1 for Mako robot installations, both in the US and internationally. That's their surgical robotics platform, and utilization rates are climbing. Plus they just got European approval for Pangaea - that's their trauma plating system that's been driving explosive growth in the US.**JORDAN:** And let's not forget the M&A activity. They announced they're acquiring Amplitude Vascular Systems, which gets them into the intravascular lithotripsy space. That's basically using sound waves to break up calcified plaque in blood vessels.**ALEX:** Kevin Lobo was really bullish on that deal during the Q&A. He said it fits perfectly with their existing peripheral vascular business through Inari, which they bought last year. Same call points, same physicians.**JORDAN:** Speaking of the Q&A, there were some great nuggets in there. One analyst asked about competitive dynamics in orthopedics, and Lobo basically said "bring it on." He mentioned they expect to keep outgrowing the orthopedic market by 200 to 300 basis points, just like they have been.**ALEX:** I loved his comment about their robotics portfolio too. He said the new Mako RPS - that's their handheld robotic system - is getting great feedback, especially in ambulatory surgery centers. It's like a stepping stone for surgeons who find full Mako too intimidating.**JORDAN:** The international story is pretty compelling too. While the US grew 1.9%, international was up 3.9% despite the cyber issues. Lobo highlighted Japan as their second-largest market outside the US, and it's experiencing "tremendous growth."**ALEX:** And they're just gettingThis episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're breaking down Apple's Q2 2026 earnings – and folks, this wasn't just any ordinary quarter. Jordan, before we jump in, I need to share our disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex, and wow – where do we even start with this Apple quarter? I mean, we've got blockbuster numbers AND a major leadership transition announcement all in one call.**ALEX**: Right? Tim Cook announcing he's stepping down as CEO after 15 years to become Executive Chairman, with John Ternus taking over in September. But let's start with the financial fireworks. Apple absolutely crushed it with $111.2 billion in revenue – that's up 17% year-over-year and a March quarter record.**JORDAN**: And that revenue beat came despite supply constraints, which is remarkable. iPhone was the star of the show at $57 billion, up 22% year-over-year. Alex, when you're supply constrained and still growing at over 20%, that tells you something about the underlying demand strength.**ALEX**: Absolutely. And it wasn't just iPhone – they had double-digit growth across every geographic segment, including Greater China which grew 28% and hit a quarterly record. The iPhone 17 family seems to be resonating incredibly well with customers.**JORDAN**: Let's talk about those supply constraints because this is fascinating from an operational perspective. Cook was pretty transparent about this – the main constraint is availability of advanced nodes for their SoCs, not memory as some might have expected. And get this – for Mac specifically, they're seeing higher than expected demand for Mac mini and Mac Studio because customers are recognizing these as powerful AI platforms.**ALEX**: And don't forget the MacBook Neo! Cook said customer response has been "off the charts" with higher than expected demand. They set a March record for customers new to Mac, partly due to the Neo. It sounds like Apple's strategy of bringing Mac to more people at a breakthrough price is really working.**JORDAN**: Services hit another all-time record at $31 billion, up 16%. But here's what caught my attention – they announced they're ending their formal net cash neutrality target. CFO Kevan Parekh said they want more flexibility to evaluate cash and debt independently.**ALEX**: That's a big strategic shift. They authorized another $100 billion in share buybacks and raised the dividend 4% to 27 cents per share. It sounds like they want more financial flexibility as they ramp up AI investments, which brings us to the elephant in the room – their AI strategy.**JORDAN**: Cook was asked about agentic AI and the future of smartphones, and while he didn't reveal future products, he emphasized how thrilled they are with Apple Intelligence integration. The company is clearly investing heavily – R&D spending is accelerating much higher than overall company growth.**ALEX**: The memory cost situation is interesting though. Cook was pretty direct about this – they expect "significantly higher memory costs" in the June quarter and said beyond that, memory costs will drive "an increasing impact" on their business. When analysts pushed on margins, he said they'll "look at a range of options."**JORDAN**: That's code for potential pricing actions, right? With 99% customer satisfaction on the iPhone 17 family in the US, they clearly have pricing power. But Cook was coy about whether they'd focus on market share gains or profitability in this cost environment.**ALEX**: Let's talk about the guidance. They're expecting total company revenue to grow 14% to 17% year-over-year in June, which assumes coThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.**JORDAN**: And I'm Jordan. Today we're diving into Southern Company's Q1 2026 earnings call, and wow - this utility is absolutely crushing it in the data center boom.**ALEX**: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. So Alex, let's start with the numbers because they're pretty impressive.**ALEX**: They really are. Southern posted adjusted earnings per share of $1.32 for Q1, which was 9 cents higher than last year and beat their own estimate by 12 cents. That's solid execution right there.**JORDAN**: What's driving this outperformance? Because utilities aren't exactly known for big earnings surprises.**ALEX**: Here's where it gets interesting - it's all about load growth. Their weather-normal retail electricity sales jumped 2.3% year-over-year, which CEO Chris Womack called "the highest total retail sales growth that we have seen in the first quarter in recent history." But the real story is in the commercial segment.**JORDAN**: Right, commercial sales were up 4.5% when adjusted for weather, and get this - data center usage alone was up 42% year-over-year. That's not a typo, folks. Forty-two percent.**ALEX**: And they added 46,000 new residential customers to their system. The Southeast continues to be this massive economic magnet. In Q1 alone, they announced over $7 billion in capital investment and nearly 4,000 permanent jobs coming to their region.**JORDAN**: The scale of what Southern is dealing with on the large load front is just staggering. They now have 11 gigawatts of fully contracted large load agreements - that's enough to power roughly 8 million homes. And in just the last two months, they signed contracts for another 1.9 gigawatts with hyperscalers.**ALEX**: But here's what I love about their approach - these aren't your typical utility contracts. Every single large load customer has to cover their full share of costs to serve them. There are minimum bills, collateral requirements, cancellation fees. Southern isn't taking any risks here.**JORDAN**: Smart structure. And the pipeline is enormous - they're talking about over 75 gigawatts in their prospective pipeline, with 12 gigawatts in late-stage discussions through the mid-2030s. Half of that 12 gigawatts is expected to be finalized with executed contracts in the near term.**ALEX**: To put that in perspective, Jordan, Southern's entire current generating capacity is around 50 gigawatts. We're potentially talking about doubling their system over the next decade.**JORDAN**: Which brings us to the infrastructure challenge. Georgia Power just launched an RFP - that's request for proposals - for 2 to 6 gigawatts of new dispatchable generation, including thermal, battery storage, and renewables, all coming online in 2032-2033.**ALEX**: And they're not just planning - they're already building. They've got 10 gigawatts of new generation resources under development right now. Georgia Power just brought two new battery storage systems online, totaling nearly 200 megawatts of capacity.**JORDAN**: The financial implications are massive too. CFO David Poroch mentioned that if they get selected for company-owned resources in these RFPs, we could be looking at about $2 billion of incremental capital expenditure per gigawatt. That's serious money.**ALEX**: Speaking of money, they just secured something pretty remarkable - $26.5 billion in loan agreements with the Department of Energy. This is historic low-cost financing that's projected to save customers $7 billion over the 30-year term.**JORDAN**: That's huge for their capital structure. It reduces their reliThis episode includes AI-generated content.

# Beta Finch Podcast Script: Merck Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack here.**JORDAN:** That's right, Alex. And before we jump in, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX:** Thanks, Jordan. Now, let's talk about the headline numbers. Merck reported revenue of $16.3 billion for Q1, which represents 5% growth year-over-year, or 3% excluding foreign exchange impacts. But here's the kicker - they actually posted a loss of $1.28 per share.**JORDAN:** Right, and that loss is entirely due to a massive one-time charge. Merck took a $9 billion hit related to their acquisition of Cidara Therapeutics. Without that charge, they would have been profitable. In fact, they raised their full-year guidance, which tells you management feels pretty good about the underlying business.**ALEX:** Exactly. They bumped up their revenue guidance to between $65.8 billion and $67 billion for the full year, and raised their EPS guidance to $5.04 to $5.16. But Jordan, let's talk about what's really driving this growth - because it's not just KEYTRUDA anymore.**JORDAN:** That's the big story here, Alex. Yes, KEYTRUDA sales were still strong at $8 billion, up 8%, but what caught my attention was how diversified their growth drivers are becoming. WINREVAIR, their pulmonary arterial hypertension drug, hit $525 million in sales. That's a relatively new product showing real traction.**ALEX:** And then there's WELIREG, their oral HIF-2-alpha inhibitor, which saw 43% growth to $199 million. Management highlighted they have over 20 new products launching with what they called "blockbuster potential." CEO Rob Davis mentioned a potential commercial opportunity of over $70 billion by the mid-2030s from these new growth drivers alone.**JORDAN:** Those are big numbers, Alex. But let's talk about some challenges too. GARDASIL sales dropped 22% to $1.1 billion, mainly due to lower demand in China and Japan. And their new RSV prevention drug ENFLONSIA had minimal sales in Q1, though that was expected due to seasonality.**ALEX:** True, but management seemed confident about the RSV product ramping up in the second half of the year. What really stood out to me from the call was their focus on AI and partnerships. They announced a multi-year deal with Google Cloud for AI capabilities, plus expanded collaborations with Tempus AI and the Mayo Clinic.**JORDAN:** That's a smart move, especially in drug development where AI could potentially accelerate research timelines. Speaking of their pipeline, they had some interesting updates. The FDA approved their HIV drug IDVYNSO, and they're expecting several priority reviews in the coming months for cancer treatments.**ALEX:** The pipeline discussion was fascinating. Dr. Dean Li, their research chief, mentioned they have 17 Phase III studies ongoing for their antibody-drug conjugate sac-TMT, with 13 of those in "first mover" indications. That could be huge if those trials are successful.**JORDAN:** And let's not forget the Terns Pharmaceutical acquisition they're working on. They're paying about $5.8 billion for TERN-701, a chronic myeloid leukemia drug candidate. Management thinks it has "multibillion-dollar commercial potential."**ALEX:** During the Q&A, analysts were clearly focused on the pipeline readouts coming this year. There was a lot of discussion about their ophthalmology programs and cancer combination therapies. One thing that struck me was how confident management sounded about their diversification strategy.**JORDAN:** Absolutely. CFO Caroline Litchfield mentionedThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches.**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth.**ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market?**JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point.**ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years.**JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands.**ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically.**JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting.**ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand?**JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores.**ALEX:** What makes on! PLUS special?**JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience.**ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products.**JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products.**ALEX:** Let's talk about that CEO transition. Gifford is stepping dThis episode includes AI-generated content.

# Beta Finch Podcast Script: Mastercard Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the corporate speak to bring you what really matters from the latest earnings calls. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Mastercard's Q1 2026 results - and folks, there's a lot to unpack here.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And what a quarter this was for Mastercard! The numbers are pretty impressive - net revenue up 12% and net income jumping 15% year-over-year on a currency-neutral basis. EPS came in at $4.60, which included a nice 10-cent boost from share buybacks.**ALEX:** That's solid growth, but what caught my attention was how they're navigating some pretty significant headwinds. CEO Michael Miebach was pretty upfront about the geopolitical tensions affecting their cross-border business, particularly related to the Middle East conflict. Jordan, what did you make of their approach to this challenge?**JORDAN:** It's interesting, Alex. They're seeing pressure on cross-border travel metrics - growth slowed from 8% to just 2% in the first four weeks of April. But here's what I found compelling: Miebach talked about how they immediately pivoted to help customers understand shifting spending patterns. Within 24 hours of the conflict escalating, they had a website up for Middle East customers showing where spending was moving.**ALEX:** That's the kind of agility you want to see from management. And they're not just sitting back - they're actively helping customers adapt. Speaking of adaptation, let's talk about some of the more futuristic stuff they're working on. This whole AI agent commerce thing sounds pretty wild.**JORDAN:** Oh, the agentic commerce initiative is fascinating! So basically, they're preparing for a world where AI agents can make purchases on your behalf. They've got something called "Mastercard Agent Pay" and they're working with heavy hitters like OpenAI, Google, and Microsoft. What's really smart is they've developed "verifiable intent" - basically a tamper-proof record of what you actually authorized an AI agent to do.**ALEX:** That sounds like it could be huge down the road, but where are we in terms of actual volume and adoption?**JORDAN:** Miebach was honest about this - they're still in early stages for volume. But the infrastructure building is critical. They've enabled nearly all Mastercards globally for Agent Pay, and they're setting the standards for how this whole ecosystem will work. It's classic Mastercard - get in early, help build the rails, then benefit as adoption scales.**ALEX:** And speaking of getting in early, they're making a big bet on stablecoins with their planned BVNK acquisition. Help our listeners understand what this is all about.**JORDAN:** Sure. So BVNK is basically a platform that helps with the messy parts of digital assets - sending, receiving, converting, and storing stablecoins. Mastercard sees stablecoins as becoming a meaningful part of money movement, especially for B2B payments, cross-border transactions, and "me-to-me" transfers like funding your own wallet. The revenue model is basis points on volume, and this opens up addressable markets that Mastercard doesn't participate in today. Plus, BVNK has those hard-to-get licenses and regulatory tools that make this space work.**ALEX:** It sounds like they're positioning themselves for a multi-rail future - not just cards, but also real-time payments and digital assets. Now, let's talk about their bread and butter value-added services. This segment grew 18% - what's driving that?**JORDAN:** This is where their data moat reallThis episode includes AI-generated content.

# Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.**ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.**JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.**ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.**JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.**ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.**JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.**ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.**JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP, GLP-1, and glucagon. In the TRANSCEND T2D1 trial, patients lost an average of 25 to 37 pounds while alsoThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you the insights that matter. I'm Alex, and joining me as always is Jordan. Today we're diving into Caterpillar's absolutely explosive Q1 2026 earnings call - and folks, this was a doozy.But before we dig in, I need to share an important note: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex, and wow - you're right about this being explosive. I've been covering industrial earnings for years and this Caterpillar quarter was genuinely remarkable. Let me just hit you with some numbers right off the bat - revenue jumped 22% to $17.4 billion, adjusted earnings per share shot up 30% to $5.54, and here's the kicker - their backlog grew to a record $63 billion. That's a 79% increase year-over-year.**ALEX:** Those are staggering numbers, Jordan. But what really caught my attention was the announcement during the call. Caterpillar is essentially doubling down on their data center bet. They're expanding their large reciprocating engine capacity from 2x their 2024 levels to nearly 3x. That's massive.**JORDAN:** Absolutely massive, Alex. And CEO Joe Creed was pretty candid about what's driving this - it's the AI revolution. He mentioned that since they first announced capacity expansion plans back in January 2024, their large reciprocating engine backlog has grown by more than 3.5x. Customers aren't just ordering for this year - some orders are going well into 2028.**ALEX:** What I found fascinating was how this isn't just about backup power anymore. Creed mentioned they're seeing increasing demand for prime power applications - basically data centers that want their own dedicated power generation rather than just backup systems. That's a game changer because prime power means much higher service revenue downstream.**JORDAN:** Exactly, and that service revenue story is crucial. When you sell backup generators, you get the initial sale and some maintenance. But prime power? That's ongoing fuel, parts, service contracts - it's the gift that keeps on giving. Creed even mentioned this was their sixth agreement for at least 1 gigawatt of equipment for prime power applications.**ALEX:** Let's talk numbers for investors. They raised their full-year guidance to low double-digit growth - that's up from their previous outlook. And they're projecting free cash flow will be higher than last year's $9.5 billion. But there's a cloud here - tariffs.**JORDAN:** The tariff situation is really interesting, Alex. They absorbed about $600 million in tariff costs in Q1 alone, which was actually better than their $800 million estimate. But for the full year, they're still looking at $2.2 to $2.4 billion in tariff impacts. CFO Andrew Bonfield, who's retiring after this call, was pretty matter-of-fact about it - they're working on mitigation strategies but it's definitely a headwind.**ALEX:** Speaking of Bonfield, this was his final earnings call after what sounds like an incredible run as CFO. Kyle Epley is taking over, and he seemed well-prepared during his portion of the call. Any concerns about the transition?**JORDAN:** Not really - Epley has been with the company for over 20 years and worked closely with Bonfield. What I liked was his detailed breakdown of the Q2 outlook. He's expecting continued strong growth across all segments, with Power and Energy leading the charge. He also provided really granular details on tariff impacts by segment, which shows he's got a handle on the complexities.**ALEX:** The segment performance was pretty interesting too. Construction Industries had a massive 30% sales increase, Resource Industries grew 4%, and Power and Energy was up 22%.This episode includes AI-generated content.

# Beta Finch Podcast Script: Bristol-Myers Squibb Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026 results, and there's quite a lot to unpack here.**JORDAN**: Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks for that, Jordan. Now, let's talk Bristol-Myers Squibb - ticker BMY. This pharmaceutical giant just reported Q1 results, and honestly, they seem to be firing on multiple cylinders right now.**JORDAN**: The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.**ALEX**: That's a massive shift for a company that's been dealing with patent cliffs on older drugs. What stood out to you in terms of specific products driving this growth?**JORDAN**: Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.**ALEX**: Let's talk about what CEO Chris Boerner emphasized during the call. He really hammered home three strategic priorities: focusing R&D on life-threatening diseases, executing on their growth portfolio, and maintaining disciplined capital allocation. But Jordan, what caught my attention was all the talk about late 2026 being a make-or-break period for several key programs.**JORDAN**: Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.**ALEX**: Let's break down a couple of these. Milvexian is their Factor XI inhibitor, essentially trying to create a blood thinner with less bleeding risk than current options. How big could this be?**JORDAN**: Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."**ALEX**: And then there's Cobenfy, which they're testing in Alzheimer's psychosis. This seems like a completely different approach to treating psychiatric symptoms in dementia patients.**JORDAN**: Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.**ALEX**: Now, during the Q&A, there were some really interesting exchanges. One analyst asked about their confidence levels in these trials, and Chief Medical Officer Cristian Massacesi gave pretty detailed responses about trial design and patient selection.**JORDAN**: What struck me was how specific they weThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into some fascinating quarterly results. Today we're unpacking Amphenol's absolutely monster Q1 2026 earnings call - and folks, when I say monster, I mean it. Jordan, before we jump in, I need to share our standard disclaimer with listeners.This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Now Jordan, let's talk about these numbers because they're pretty incredible.**JORDAN:** Alex, I've been covering tech earnings for years, and this Amphenol quarter is genuinely jaw-dropping. They just posted record sales of $7.6 billion - that's up 58% year-over-year and 33% organically. But here's the kicker - their IT datacom segment, which is heavily exposed to AI infrastructure, grew 81% organically. Eighty-one percent!**ALEX:** That's insane growth. And their guidance for Q2 is equally aggressive - they're projecting $8.1 to $8.2 billion in sales, which would be another 43-45% year-over-year growth. What's driving this AI boom for them specifically?**JORDAN:** So Amphenol makes connectors and interconnect products - basically the plumbing that connects all the components in data centers. CEO Adam Norwitt made a really interesting point on the call. He said that virtually all of their sequential growth in IT datacom came from AI-related products. These aren't just any connectors - they're high-speed, high-power interconnects that AI systems absolutely depend on.**ALEX:** And they just made a huge acquisition to strengthen this position, right? The CommScope deal?**JORDAN:** Exactly. They closed the CommScope acquisition in January for what appears to be around $2.1 billion based on the context. This gives them fiber optic capabilities to complement their copper products. Norwitt was really excited about this on the call - he kept emphasizing that they now have "the industry's broadest range of high-speed copper, power, and fiber optic interconnect products." **ALEX:** That seems strategic because there's this big debate in the AI world about whether future systems will use copper or fiber optic connections, right?**JORDAN:** Exactly, and that's where Amphenol's positioning gets really smart. There was a great exchange during the Q&A about co-packaged optics and other next-gen technologies. Norwitt basically said they don't care which technology wins because they play in both spaces now. His quote was memorable: "no matter what, there's going to be more interconnect."**ALEX:** So they're betting on the overall trend rather than a specific technology. That makes sense. What about their margins? Because with this kind of growth, you'd expect some operational challenges.**JORDAN:** That's the really impressive part. Despite integrating a major acquisition and growing at breakneck speed, they maintained adjusted operating margins of 27.3%. That's actually up 380 basis points year-over-year. CFO Craig Lampo attributed this to "robust operating leverage" - basically, they're scaling efficiently.**ALEX:** And this isn't just an AI story, is it? Looking at their other segments, they seem pretty diversified.**JORDAN:** Right, and this is important for investors to understand. While IT datacom is now 41% of their business, they're still seeing solid growth elsewhere. Defense was up 25% organically, industrial up 16% organically, even automotive grew modestly. Their book-to-bill ratio was 1.24 to 1, and every single end market had a positive book-to-bill.**ALEX:** That book-to-bill number is telling - it means orders are coming in 24% faster than they can ship products. There was an interesting question about capacity constraints and long-term supply agreements. WhThis episode includes AI-generated content.

# Beta Finch Podcast Script: Qualcomm Q2 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Qualcomm's second quarter 2026 results, and wow, there's a lot to unpack here.**JORDAN**: Absolutely, Alex. But before we jump in, let me remind our listeners: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks, Jordan. Now, let's talk numbers. Qualcomm delivered $10.6 billion in revenue with non-GAAP earnings per share of $2.65, hitting the high end of their guidance. But the real story here isn't just the headline numbers—it's this massive pivot toward what CEO Cristiano Amon calls "agentic AI" and their diversification strategy.**JORDAN**: Right, and let's break down those business segments because they tell an interesting story. QCT, their chip business, brought in $9.1 billion, while licensing pulled in $1.4 billion. But here's what caught my attention—automotive hit another record at $1.3 billion, up 38% year-over-year. They're now at a $5 billion annualized run rate and expect to exit fiscal 2026 above $6 billion.**ALEX**: That automotive growth is impressive, but I want to talk about this elephant in the room—the China handset situation. They're dealing with what they call "memory industry dynamics" that are causing handset OEMs, particularly in China, to be super cautious with their build plans.**JORDAN**: Exactly. CFO Akash Palkhiwala was pretty candid about this. He said their China Android shipments are "meaningfully below the scale of end consumer handset demand" because OEMs are drawing down channel inventory due to memory supply issues and price increases. But here's the key—they believe Q3 will be the bottom, with sequential growth expected after that.**ALEX**: So basically, people are still buying phones, but manufacturers aren't ordering as many chips because they're worried about memory costs. It's like a supply chain traffic jam. But what really fascinated me was Amon's vision for where AI is heading. He's talking about this shift from basic AI inference to what he calls "agentic AI"—AI that can orchestrate multi-step tasks and run continuously in the background.**JORDAN**: And this is where Qualcomm thinks they have a competitive advantage. Amon argued that agent orchestration is predominantly CPU-bound, and he claims Qualcomm has "the world's best performing CPU across smartphones, PCs, auto, and soon the data center." That's a bold claim, but they're backing it up with some interesting product launches.**ALEX**: Speaking of bold claims, let's talk about their data center ambitions. This was probably the biggest surprise in the call. They announced they're starting shipments to a "leading hyperscaler" in December for a custom silicon engagement. When pressed for details, Amon was pretty tight-lipped but called it a "multi-generation engagement."**JORDAN**: The timing on that is interesting because it suggests they've been working on this longer than many people realized. Remember, they acquired AlphaWave earlier, which gives them custom ASIC capabilities. But Amon mentioned they've been talking to data center customers for several quarters even before that acquisition.**ALEX**: One analyst asked a great question about the competitive landscape, especially with ARM now trying to vertically integrate and NVIDIA focusing on inference. Amon's response was fascinating—he basically laid out how the AI market is evolving from training-focused to inference-focused to now this new phase of "agentic" experiences.**JORDAN**: Right, and his argument is that as AI becomes more about generating demand for tokens rather than just generating the tokens themselves, you need different types ofThis episode includes AI-generated content.

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is Jordan. Today we're diving into Microsoft's absolutely explosive Q3 2026 earnings report that just dropped. Jordan, before we get started, I need to remind our listeners that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Thanks Alex, and wow - where do we even begin with these Microsoft numbers? They just reported record results across the board. Revenue hit $82.9 billion, up 18% year-over-year, and earnings per share came in at $4.27. But the real headline here is their AI business - it's now at a $37 billion annual run rate, growing 123% year-over-year!ALEX: That AI growth rate is just staggering. But let's put this in perspective - Microsoft Cloud overall generated $54 billion in revenue, up 29%. So AI is becoming a massive piece of their puzzle. What really caught my attention was Satya Nadella talking about how we're at the beginning of "one of the most consequential platform shifts" as agents become the dominant workload.JORDAN: Absolutely, and you can see this playing out in their Copilot numbers. Microsoft 365 Copilot now has over 20 million paid seats - that's 250% growth year-over-year. Even more impressive, they're seeing weekly engagement levels that match Outlook. Think about that - people are using Copilot as much as they use email!ALEX: That's a great point about user engagement. And they shared some fascinating customer wins - Accenture alone has over 740,000 seats, which is their largest Copilot deal to date. Companies like Bayer, Johnson & Johnson, and Mercedes are all committing to 90,000+ seats. But Jordan, what I found really interesting was this shift in business model that Amy Hood kept emphasizing.JORDAN: Yes! The transition from traditional per-seat pricing to what they're calling "seats plus consumption." It's happening across their portfolio - from productivity to coding to security. GitHub Copilot actually announced they're moving to usage-based pricing starting June 1st. This is huge because it means as customers use these AI tools more intensively, Microsoft's revenue can scale accordingly.ALEX: And they're seeing that intensity increase dramatically. Copilot queries per user were up nearly 20% just quarter-over-quarter. Usage of their first-party agents is up 6x year-to-date. Amy Hood mentioned that in customer service, nearly 60% of their customers are already purchasing usage-based credits.JORDAN: The infrastructure side of this story is equally compelling. They added another gigawatt of capacity this quarter and are on track to double their overall footprint in two years. But here's the kicker - they're still capacity constrained and expect to remain so through at least 2026. That's both a challenge and an opportunity.ALEX: Speaking of infrastructure, their CapEx guidance is eye-popping. They're expecting over $40 billion in Q4 alone, and for calendar 2026, they're projecting roughly $190 billion in capital expenditures. That includes about $25 billion from higher component pricing. When an analyst asked about investor concerns over CapEx growing faster than revenue, Amy Hood made a compelling case.JORDAN: Right, she pointed to their $627 billion in remaining performance obligations - that's contracted revenue they still need to deliver. With demand consistently exceeding supply and usage intensity growing, they feel confident about the ROI on these investments. Satya added that they want to be ready when model capabilities hit those exponential moments - like when agent mode in Excel suddenly "started working."ALEX: Let's talk about the segment performance. Productivity and Business Processes hit $35 billion in revenue, up 17%. Intelligent Cloud was $34.7 billThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT: Meta Q1 2026 Earnings**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Meta's Q1 2026 earnings call, and wow - there's a lot to unpack here.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Jordan, Meta just reported some pretty impressive numbers - $56.3 billion in total revenue, up 33% year-over-year. That's a monster quarter!**JORDAN:** Absolutely, Alex. And that earnings per share of $10.44 really caught my attention, though there's a big asterisk there - they had an $8 billion tax benefit that boosted things significantly. Without that, we're looking at $7.31 per share, which is still solid but gives us a clearer picture of the underlying performance.**ALEX:** Right, and speaking of underlying performance, the engagement metrics are where things get really interesting. Mark Zuckerberg spent a lot of time talking about their new AI model called "Muse Spark" from their Meta Superintelligence Labs. This seems like their big bet on competing with OpenAI and Google in the AI race.**JORDAN:** That's the story of this earnings call, Alex. Meta is going all-in on AI, and I mean ALL-IN. They're increasing their capital expenditure guidance to $125-145 billion for 2026 - that's up from their previous range of $120-135 billion. We're talking about massive infrastructure investments here.**ALEX:** And the results seem to be paying off already. They're seeing double-digit increases in Meta AI sessions per user since launching Muse Spark. But what really stood out to me was how they're using AI to improve their core recommendation systems. On Instagram, they drove a 10% lift in Reels time spent, and on Facebook, total video time increased more than 8% globally - that's the largest quarter-over-quarter gain in four years!**JORDAN:** Those engagement improvements are crucial because that's what drives ad revenue, which was $55 billion this quarter, up 33%. But here's what's fascinating - they're not just throwing more ads at people. They're using AI to make ads more effective. They mentioned a 6% increase in conversion rates for landing page view ads and over 8 million advertisers now using their AI-powered creative tools.**ALEX:** The business AI piece is really taking off too. Susan Li mentioned they now have over 10 million weekly conversations between people and business AIs on their messaging platforms - that's up from just 1 million at the start of the year. That's 10x growth in just one quarter!**JORDAN:** And let's talk about the elephant in the room - that massive increase in contractual commitments. They added $107 billion in contractual commitments this quarter for infrastructure and cloud deals. That's not just spending money; that's locking in capacity for the next several years.**ALEX:** Which brings us to the cost management side. Meta announced they're planning workforce reductions in May. They're calling it a move toward a "leaner operating model" to help offset these substantial AI investments. It's interesting - they're betting that AI will make their remaining employees more productive.**JORDAN:** The Ray-Ban smart glasses story continues to be a bright spot too. Daily users tripled year-over-year, and they're expanding beyond just Ray-Ban to other brands. Mark mentioned this is "one of the fastest growing categories of consumer electronics ever." That's a bold claim, but the numbers seem to back it up.**ALEX:** In the Q&A, there were some really revealing moments. When asked about return on investment for all this AI spending, Zuckerberg essentially said they're following their traditional playbook: build experiencesThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn quarterly reports into conversations you'll actually want to hear. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into KLA Corporation's Q3 2026 results - and wow, what a quarter this was.Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And speaking of wow - KLA absolutely crushed it this quarter. Revenue hit $3.415 billion, which was not only up 4% sequentially but also 11% year-over-year. That beat their internal forecasts too.**ALEX:** Right, and the earnings per share story is even better - $9.40 non-GAAP EPS. But Jordan, what really caught my attention was their forward-looking commentary. They're basically saying 2027 is going to be massive for the semiconductor equipment industry.**JORDAN:** Exactly. CEO Rick Wallace made some pretty bold statements about visibility into 2027. He said there's "unprecedented demand visibility" from customers and that normally they wouldn't comment on 2027 growth rates in April of 2026, but the demand environment is giving them that confidence. They expect 2027 year-over-year growth to be higher than 2026.**ALEX:** Let's break down what's driving this optimism. KLA is the leader in process control equipment - think of them as the quality control experts for semiconductor manufacturing. Every time chip makers need to inspect their wafers or measure critical dimensions, they're likely using KLA tools.**JORDAN:** And AI is clearly the rocket fuel here. The company specifically called out AI as "a core driver of KLA's performance." They're seeing increased investment in leading-edge foundry logic and high bandwidth memory - both critical for AI applications. What's fascinating is they raised their advanced packaging revenue outlook from $635 million to approximately $1 billion for 2026.**ALEX:** That's a 57% increase! Advanced packaging is becoming crucial as chip companies try to pack more performance into smaller spaces. It's like upgrading from a studio apartment to a high-rise - you need much more sophisticated tools to make sure everything fits perfectly.**JORDAN:** The numbers tell a compelling story about market share too. KLA increased their global share in both overall wafer equipment and process control markets in 2025. In advanced packaging specifically, they gained 14 percentage points of market share and saw 70% year-over-year revenue growth.**ALEX:** Now let's talk about the elephant in the room - supply chain constraints. During the Q&A, management acknowledged they're dealing with unprecedented demand urgency from customers. CFO Brent Higgins said customers are showing "a higher level of urgency around securing capacity" than he's seen before.**JORDAN:** This creates an interesting dynamic. On one hand, it's validation of incredibly strong demand. On the other hand, it means KLA has to rapidly scale operations, hire more people, and ensure they can deliver. The good news is they seem confident about supporting the 2027 ramp.**ALEX:** Speaking of 2027, let's dig into their industry outlook. They're expecting the wafer equipment market to exceed $140 billion in 2026 - that's up from previous estimates of $135-140 billion. But here's the kicker: they think their semiconductor process control systems business will grow over 20% in 2026, significantly outpacing the broader market.**JORDAN:** The geographic and end-market mix is interesting too. For the June quarter, they're forecasting foundry logic to be about 82% of revenue with memory at 18%. Within memory, DRAM is expected to be 84% and NAND 16%. This heavy foundry weighting reflects tThis episode includes AI-generated content.

# Beta Finch Podcast Script: Amazon Q1 2026 Earnings**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's latest results. I'm Alex, and joining me as always is Jordan. Today we're diving into Amazon's blockbuster Q1 2026 earnings that just dropped, and folks, this was a quarter that reminded everyone why AMZN remains one of the most closely watched stocks in the market.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Jordan, Amazon just posted some absolutely staggering numbers. Walk us through the headline figures.**JORDAN:** Alex, these results were genuinely impressive across the board. Amazon delivered $181.5 billion in revenue, up 17% year-over-year, or 15% excluding foreign exchange impacts. But here's the kicker - operating income hit $23.9 billion with a 13.1% operating margin. Andy Jassy specifically called this their highest operating margin ever.**ALEX:** That margin number really jumps out. For a company of Amazon's scale to be hitting record profitability while still growing at this pace is remarkable. But the real story here seems to be AWS, right?**JORDAN:** Absolutely. AWS was the star of the show. Revenue hit $37.6 billion with 28% year-over-year growth - that's the fastest growth rate AWS has seen in 15 quarters. And get this - Jassy said it's very unusual for a business to grow this fast on a $150 billion annualized run rate. The last time they saw growth at this clip, AWS was roughly half the size.**ALEX:** The AI story is clearly driving a lot of this growth. What stood out to you from their AI commentary?**JORDAN:** The AI numbers are just mind-blowing when you put them in context. Jassy mentioned that three years after AWS launched, it had a $58 million revenue run rate. But in the first three years of this AI wave, AWS's AI revenue run rate is over $15 billion - that's 260 times larger. He said they've never seen a technology grow as rapidly as AI.**ALEX:** And they're not just riding the wave - they're building their own chips to compete. Tell us about their custom silicon story.**JORDAN:** This might be the most underappreciated part of Amazon's business right now. Their chips business saw nearly 40% quarter-over-quarter growth, with an annual revenue run rate now over $20 billion. But here's the fascinating part - Jassy said if their chips business sold chips like other leading chip companies do, their annual revenue run rate would be $50 billion. He believes they're now one of the top three data center chip businesses in the world.**ALEX:** That's incredible positioning, especially when you consider the supply constraints everyone's dealing with. Speaking of which, how are they handling the memory and component cost inflation that's hitting everyone right now?**JORDAN:** Jassy was pretty candid about this challenge. He said component costs, particularly memory, have "skyrocketed" due to insufficient capacity for the demand. But interestingly, he sees this as actually helping AWS win more enterprise customers. Since cloud providers are getting priority from suppliers, companies with on-premises infrastructure are being pushed to migrate to the cloud faster because AWS has more supply than they can get on their own.**ALEX:** That's a fascinating competitive dynamic. Now, outside of AWS, how did the core retail business perform?**JORDAN:** The retail side showed impressive momentum too. Units grew 15% year-over-year - Jassy said that's the highest they've seen since the tail end of COVID lockdowns. Their grocery business is now generating more than $150 billion in gross sales, making them the second-largest grocer in the U.S.This episode includes AI-generated content.

# Beta Finch Podcast Script - Visa Q2 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to break down Visa's absolutely stellar Q2 2026 results. Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex, and wow - where do we even start with these numbers? Visa just delivered what CEO Ryan McInerney called "the strongest net revenue growth since 2022" - and when you exclude post-pandemic recovery periods, we're talking about the strongest growth since 2013!**ALEX:** The headline numbers are just incredible. Net revenue jumped 17% year-over-year to $11.2 billion, and earnings per share grew 20%. But Jordan, what really caught my attention was how broad-based this strength was across all their business segments.**JORDAN:** Absolutely. Let's break this down for our listeners. Payments volume grew 9% to $3.7 trillion - that's trillion with a T - and they processed 66 billion transactions, also up 9%. But here's what's really interesting: their Value-Added Services business, which is becoming a huge growth driver, jumped 27% and now represents 30% of their total revenue.**ALEX:** That VAS number is crucial because it shows Visa isn't just a traditional payments processor anymore. They're becoming this comprehensive financial technology platform. Ryan McInerney spent a lot of time talking about four key growth drivers, and AI-powered "agentic commerce" was front and center.**JORDAN:** Right, and I have to admit, some of this agentic commerce stuff sounds pretty futuristic. Essentially, they're betting that AI agents - think ChatGPT but for shopping - will create entirely new categories of transactions. These agents might split purchases across multiple transactions to optimize pricing, or even pay for their own data consumption transaction by transaction.**ALEX:** It sounds wild, but McInerney made a compelling case. He said agents will prefer to use Visa cards because they offer privacy, broad acceptance, built-in security protections, and rewards. Plus, Visa already has 5 billion credentials across 200 countries - that's a massive head start.**JORDAN:** The stablecoin strategy was equally fascinating. They're positioning themselves as what McInerney called a "hyperscaling bridge layer" between cryptocurrency infrastructure and real-world applications. They now have over 160 stablecoin card programs globally, and that payment volume grew nearly 200% year-over-year.**ALEX:** And get this - they're settling $7 billion annually in stablecoins with their financial partners, up more than 50% just since last quarter. They've added five new blockchains for settlement, bringing their total to nine. This isn't some distant future play - it's happening right now.**JORDAN:** Let's talk about that Wells Fargo announcement because that was a huge validation of their Pismo acquisition. Wells Fargo is migrating to Pismo's core account ledger as part of their banking modernization. When you can land one of the biggest banks in the US, that's a pretty strong signal about your technology.**ALEX:** CFO Chris Suh was really bullish about their guidance too. They raised their full-year net revenue growth outlook to "low double-digit to low teens" - and they specifically mentioned increased client enthusiasm around the FIFA World Cup driving higher value-added services revenue.**JORDAN:** The FIFA example he gave was incredible. They partnered with one client in Latin America with nearly 20 million cards for FIFA campaigns. In just over three months, that client saw a 10% lift in active cards, and Visa generated $10 million in VAS revenue. That's thThis episode includes AI-generated content.

# Beta Finch Podcast Script: Mondelez Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're diving into Mondelez International's Q1 2026 results - and folks, this one's got some interesting twists.Now, before we get into the snack food giant's performance, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And what a quarter this was for Mondelez. Right off the bat, we're seeing some really compelling geographic dynamics here. Emerging markets absolutely crushed it with 6.3% growth, while developed markets are showing signs of recovery after some challenging periods.**ALEX**: That's right. And Jordan, I think what stood out to me most was CEO Dirk Van de Put's commentary about the consumer landscape. It's this tale of two worlds - you've got emerging markets like India showing double-digit growth, but then you have this underlying fragility everywhere due to Middle East tensions affecting energy and commodity costs.**JORDAN**: Exactly. And let's talk numbers for a second. That emerging markets growth of 6.3% is really broad-based. India was particularly strong with double-digit growth in both chocolate and biscuits. They even launched Biscoff in India and the line is already sold out - that's the kind of execution you want to see.**ALEX**: Speaking of Biscoff, this partnership keeps coming up as a major growth driver. Van de Put seemed genuinely excited about it, calling it something that will be "really quite big for them and for us in the coming years." They're not just doing biscuits - they're incorporating Biscoff cream and crumbs into their chocolate products too.**JORDAN**: And that innovation strategy is fascinating. They're making what Van de Put called "bigger and fewer bets." Instead of throwing everything at the wall, they're focusing on four key areas: well-being products with protein and fiber, premium chocolate, the Biscoff partnership, and cakes and pastries through acquisitions and brand extensions.**ALEX**: Now, here's where it gets interesting from a financial perspective. CFO Luca Zaramella said they're ahead of expectations in Q1, but they're maintaining their EPS guidance for 2026. Why? Because they're facing unexpected headwinds from the Middle East situation - extra costs for alternative supply routes, higher oil prices affecting some regulated markets.**JORDAN**: Right, and this is where management's capital allocation philosophy really shows. Zaramella was pretty clear - if they do see EPS upside materializing, they're going to invest it back into the business rather than just dropping it to the bottom line. They're playing the long game here, especially with their commitment to "strong 2027 EPS growth."**ALEX**: Let's talk about Europe for a moment, because this was a real bright spot. They completed most of their retail negotiations ahead of Easter, saw market share gains, and had what Van de Put called a "very robust Easter season." The Biscoff partnership is performing particularly well in Australia and New Zealand too.**JORDAN**: And the competitive dynamics in Europe around chocolate pricing seem to have stabilized. Remember, there were big concerns about cocoa price volatility and how that might trigger a pricing war. But Van de Put said customer negotiations went well, and they're not seeing any major price movements right now. The industry seems to be waiting to see what the main crop brings.**ALEX**: The U.S. market is more challenging though. Van de Put was pretty candid about consumer confidence remaining low, with expectations it could deteriorate further. But here's the thing - they'reThis episode includes AI-generated content.

# Beta Finch Podcast Script: Regeneron Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex.**JORDAN:** And I'm Jordan. Today we're breaking down Regeneron's first quarter 2026 results, and folks, this biotech giant is firing on all cylinders.**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. Now Alex, let's talk numbers because Regeneron just posted some impressive results. Revenue jumped 19% to $3.6 billion, and non-GAAP earnings per share grew 15%. Those are solid double-digit growth numbers across the board.**ALEX:** What really caught my attention is the DUPIXENT story. This drug is becoming an absolute juggernaut - global net sales hit $4.9 billion in the quarter, up 31% on a constant currency basis. Jordan, we're looking at annualized sales approaching $20 billion for this single drug.**JORDAN:** It's incredible when you put it in perspective. DUPIXENT is now treating over 1.4 million patients worldwide, and they keep expanding into new indications. This quarter alone, they got approval for allergic fungal rhinosinusitis and chronic spontaneous urticaria in younger patients. It's like they're building a franchise within a franchise.**ALEX:** Speaking of franchises, let's talk about their eye drug portfolio. EYLEA HD had a strong quarter with U.S. sales of $468 million, up 52% year-over-year. But here's the interesting dynamic - while EYLEA HD is growing rapidly, the original EYLEA is declining as expected, down 36%. It's a classic product transition story.**JORDAN:** And there's still some uncertainty hanging over that transition. They're waiting on FDA approval for the EYLEA HD prefilled syringe, which missed its April deadline. Management expects a decision this quarter, but it shows how regulatory timing can impact even established companies like Regeneron.**ALEX:** Now, what really excited me during the call was the pipeline discussion. CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos laid out some compelling near-term catalysts. They've got this complement inhibitor cemdisiran for myasthenia gravis that showed really impressive Phase 3 results.**JORDAN:** The data on that was striking. Their drug delivered a 2.3-point improvement compared to placebo, which actually outperformed existing treatments that showed 1.6 to 1.9 points in their trials. Plus, it's dosed quarterly versus every two weeks for competitors. That convenience factor could be huge.**ALEX:** And then there's their obesity play with olatorepatide. This is where Regeneron is trying to differentiate in the crowded GLP-1 space. Their strategy is fascinating - they want to combine this obesity drug with their cholesterol drug Praluent.**JORDAN:** George Yancopoulos made a compelling pitch on this during the Q&A. He basically said, imagine you have a GLP-1 that works as well as the best ones out there, but also lowers your bad cholesterol by 50% and reduces cardiovascular risk. Why would anyone choose a different GLP-1? It's an interesting value proposition in a competitive market.**ALEX:** What struck me about that answer is how confident they sounded. Yancopoulos said it would be a "no-brainer" choice for physicians and patients. That's either brilliant positioning or they're setting themselves up for disappointment. Time will tell.**JORDAN:** One moment that really stood out was when they announced they're giving away their new gene therapy, Otarmeni, for free in the U.S. This treats genetic hearing loss in children, and they got FDA approval just last week.**ALEX:** That was such an interesting strategic decision. Schleifer said they'rThis episode includes AI-generated content.

# Beta Finch Podcast Script: AbbVie Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results. **JORDAN**: Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Absolutely. Now Jordan, AbbVie just delivered what I'd call a knockout quarter. They beat expectations across the board and raised guidance - what stood out to you first?**JORDAN**: The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.**ALEX**: And they're not just celebrating - they're doubling down. They raised their full-year EPS guidance by 12 cents to between $14.08 and $14.28. What's driving this confidence?**JORDAN**: Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.**ALEX**: The Skyrizi story is fascinating because it shows how a well-positioned drug can dominate even in a competitive landscape. Jeff Stewart, their commercial head, mentioned they have "over 4x basically the in-play share" versus their next competitor. How sustainable is that kind of dominance?**JORDAN**: That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.**ALEX**: Speaking of competition, one analyst specifically asked about competitive pressure, and I found Stewart's response really telling. He basically said their audit data shows NBRx - new prescriptions - hitting all-time highs despite having incredibly high market share already. That suggests real physician preference, not just early adoption.**JORDAN**: Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.**ALEX**: But here's where it gets really interesting - their combination strategy. Tell our listeners about this Skyrizi plus alpha-4 beta-7 antibody data.**JORDAN**: This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."**ALEX**: The R&D pipeline seems to be the real story here. They're not just maintaining current success - they're building the next generation. What else caught your attention?**JORDAN**: Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a 270-hour half-life, they're talking about potential monthly dosing, which could be huge for patient compliance.**ALEX**: And let's not forget neuThis episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the latest insights from corporate America's quarterly results. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into T-Mobile's Q1 2026 earnings call, and folks, this was quite a performance from the Un-carrier.Before we get started, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And wow, T-Mobile really came out swinging this quarter. Let's start with the headline numbers because they're pretty impressive. Service revenue grew 11% year-over-year - that's four times faster than their closest competitor. But what really caught my eye was their customer satisfaction score, or NPS, hitting 45 - that's over 20% higher than their nearest rival.**ALEX**: That NPS number is huge, Jordan. It really speaks to their strategy of providing "best network, best value, and best experience" all in one package. CEO Srinivasan Gopalan kept hammering this point that customers don't need to make trade-offs anymore with T-Mobile. And the numbers back it up - they added 217,000 postpaid net accounts, up 6% year-over-year, while also growing their average revenue per account by 3.9%.**JORDAN**: Exactly. That's the holy grail - growing both customer volume AND revenue per customer. Speaking of growth, their broadband business continues to be a monster. They added over 500,000 broadband customers this quarter and called themselves "the fastest-growing ISP in America" yet again. They're targeting 15 million broadband customers by 2030, and here's the kicker - that projection assumes they don't buy any more spectrum and doesn't factor in 6G improvements.**ALEX**: The broadband story is fascinating because they're using what they call "fallow capacity" on their 5G network. Essentially, they've built this massive network infrastructure, and during off-peak times, they can sell that unused capacity as home internet service. It's brilliant from a capital efficiency standpoint.But Jordan, I think the most intriguing part of this call was their discussion about AI and what they're calling "physical AI." They announced a partnership with Figure AI to connect humanoid robots to their 5G Advanced network.**JORDAN**: This is where things get really futuristic, Alex. T-Mobile is positioning itself at the intersection of AI and connectivity. They talked about building AI capabilities directly into their network core, and they're already beta-testing something called "Live Translation" that can translate your voice into 80 different languages in real-time. But the physical AI angle is what has me excited - they see a world where their network becomes the backbone for robotics and automation.**ALEX**: The key insight from network chief John Saw was that T-Mobile built their 5G Advanced network specifically with this future in mind. They have innovations like uplink transmit switching and higher transmit power that give them advantages for these AI applications. It's not just about faster phones - they're thinking about robots, autonomous systems, and edge computing.**JORDAN**: And that brings us to their guidance updates. CFO Peter Osvaldik raised several key metrics. They're now expecting 950,000 to 1.05 million total postpaid net account additions for the full year, up from previous guidance. Core adjusted EBITDA guidance went up by $100 million at the low end to $37.1-37.5 billion. Free cash flow guidance also increased by $100 million to $18.1-18.7 billion.**ALEX**: Those guidance raises show real confidence in the business momentum. But what really caught investors' attention was the announcement that they're increasing their shareholder return authorization by $3.6 billion toThis episode includes AI-generated content.

# Beta Finch Podcast Script: Starbucks Q2 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into Starbucks' second quarter 2026 results, and folks, this is a story about a turnaround that's actually working.**ALEX:** Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Right, and what a quarter to analyze! Starbucks just delivered something they haven't done in over two years - simultaneous top and bottom line growth.**ALEX:** The numbers are pretty impressive. Revenue hit $9.5 billion, up 9% year-over-year. But Jordan, what really caught my attention was that earnings per share jump - $0.50, up 22% from last year.**JORDAN:** Exactly! And CEO Brian Niccol was clearly excited about this milestone. He called it "a turn in our turnaround," which is quite the statement. The global comparable sales growth of 6% was driven by what he described as "terrific performance across the business, especially in the U.S."**ALEX:** Let's break down those U.S. numbers because they're really telling. U.S. comps accelerated to over 7%, with more than 4 percentage points coming from transaction growth. Niccol mentioned they haven't seen this kind of transaction strength in three years.**JORDAN:** That transaction growth is huge, Alex. It means people are actually visiting more, not just spending more per visit. And here's what's fascinating - they're seeing broad-based growth across all income levels and age demographics. In this economic environment, that's remarkable.**ALEX:** Speaking of remarkable, let's talk about their "Back to Starbucks" strategy. Niccol really emphasized their "Green Apron Service" model. Jordan, can you explain what they're tracking here?**JORDAN:** Sure! They use something called a "Grow scorecard" that tracks customer comments, throughput, staffing, and food safety. They measure stores on a 5-shot system, and since launching this in October, they've seen over a 30 percentage point increase in stores delivering 4 or more shots. But here's the kicker - about 40% of stores still aren't at that 4-shot level, so there's room to grow.**ALEX:** That's a great operational insight. And internationally, all top 10 markets, including China, posted positive comparable sales for the first time in 9 quarters. Though there's a big strategic shift happening with China, isn't there?**JORDAN:** Absolutely. They completed their transaction with Boyu Capital, transitioning China to a joint venture model. CFO Catherine Smith mentioned this deal is valued at more than $13 billion, and Starbucks received about $3.1 billion in cash proceeds. Starting in Q3, China will be deconsolidated from their financials.**ALEX:** Now let's talk guidance, because management got pretty confident here. They raised their global comparable sales growth guidance to "5% or better" and boosted their EPS range to $2.25 to $2.45.**JORDAN:** Right, and when analysts pressed on why the EPS raise wasn't even higher given the strong performance, Smith was candid about macro headwinds. She mentioned elevated coffee prices - almost a dollar per pound year-over-year - and tariff impacts, though both are expected to moderate in the back half of the year.**ALEX:** One thing that jumped out in the Q&A was the discussion about their rewards program. They just redesigned it in March, and typically that causes some disruption. But Niccol said membership actually grew, which is unusual for that quarter.**JORDAN:** That's impressive execution. The new program has three tiers - green, gold, and reserve - and they introduced a popular 60-star redemption option that accounts for about a third of alThis episode includes AI-generated content.

# Beta Finch Podcast Script: Booking Holdings Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Booking Holdings' Q1 2026 results - and folks, this one's got some interesting twists.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And what a quarter this was for Booking. On the surface, the numbers look solid - revenue up 16% to $5.5 billion, adjusted EBITDA growing 19% to about $1.3 billion. But dig deeper and there's a significant geopolitical shadow hanging over these results.**ALEX:** Absolutely. The Middle East conflict that started in late February really threw a wrench into what could have been an even stronger quarter. CEO Glenn Fogel estimated it knocked about 2 percentage points off their room night growth. Without that impact, their 6% room night growth would have been closer to 8%.**JORDAN:** That's a meaningful difference, Alex. And what struck me was how transparent management was about the impact. CFO Ewout Steenbergen broke it down pretty clearly - the Middle East represents about 4% of their global room nights from bookers in the region, but when you include inbound travel, it's about 7% of their total 2025 room nights. So this isn't a small market for them.**ALEX:** Right, and the ripple effects went beyond just the Middle East itself. They saw impacts on major transit corridors, particularly between Europe and Asia, since places like Dubai are huge connection hubs. March was especially brutal with room night growth of just 1% - half from reduced bookings, half from increased cancellations.**JORDAN:** But here's what I found encouraging - despite all this disruption, they still beat the high end of their guidance on adjusted EBITDA. And Glenn Fogel's commentary was pretty reassuring about their long-term view. He pointed out they've navigated crises before - 9/11, the financial crisis, COVID, Russia-Ukraine. The fundamental desire for travel doesn't disappear.**ALEX:** Speaking of things that don't disappear - their capital allocation strategy. Jordan, they returned a record $3.6 billion in share buybacks this quarter alone. Since 2014, they've reduced their share count by over 40% at an average price of $93 per share. That's some serious confidence in their long-term value.**JORDAN:** It really is. And you know what caught my attention? The U.S. performance. This was their fourth consecutive quarter of acceleration in the U.S., hitting low teens growth in room nights. That's impressive market share gains in what Glenn called a market where they "have room to grow."**ALEX:** The U.S. story is fascinating because it shows their strategy working. They've been talking for years about investing in the U.S. market - better products, brand awareness, supply relationships. And now we're seeing it pay off with domestic travel driving that growth and their direct channel seeing double-digit growth.**JORDAN:** And they're not just winning in accommodations. Their "Connected Trip" vision is gaining real traction. Flights were up 28%, attractions up 25%. Connected transactions - where travelers book multiple verticals with them - grew at a high teens rate, about 3x faster than their total transaction growth.**ALEX:** Let's talk AI for a moment because that was a major theme. Their Priceline AI assistant Penny is showing some promising early results. In limited testing, they're seeing conversion rate improvements from users who engage with Penny versus those who don't.**JORDAN:** The AI investments seem comprehensive too. It's not just customer-facing stuff like PeThis episode includes AI-generated content.

# Beta Finch Podcast Script - UPS Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn corporate calls into conversations you can actually follow. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into UPS's first quarter 2026 results, and wow - this was one packed earnings call.**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Right, thanks Alex. So UPS - the brown trucks we all know - just reported Q1 numbers, and there's a lot to unpack here. They're in the middle of what CEO Carol Tomé calls "the largest driver reduction in company history."**ALEX:** That's quite a statement. Let's start with the numbers though. Revenue came in at $21.2 billion, operating profit was $1.3 billion, and operating margin hit 6.2%. But Jordan, the real story here isn't just the numbers - it's this massive strategic transformation they're executing.**JORDAN:** Absolutely. The elephant in the room is Amazon. UPS has been deliberately reducing their Amazon business - they call it the "Amazon glidedown" - and they're almost done. Amazon now represents just 8.8% of total revenue, down from over 13% not too long ago.**ALEX:** I found it fascinating how Carol Tomé framed this. She said they're "overturning the old industry assumption that scale alone drives profitability." Instead, they're focusing on premium segments like small and medium businesses, B2B customers, and healthcare.**JORDAN:** And that strategy seems to be working. Their revenue per piece grew 6.5% year-over-year in the US, even as total volume dropped 8%. That's a classic example of making less revenue worth more profit.**ALEX:** Speaking of healthcare - this was a standout. UPS generated over $3 billion in healthcare revenue for the first time ever in a single quarter. Jordan, why is this so significant?**JORDAN:** Healthcare logistics is a premium business with higher margins. Think about it - if you're shipping temperature-sensitive medicines or medical devices, you need specialized handling, tracking, and delivery. You pay more for that reliability. Carol mentioned they're seeing opportunities with pharmaceutical companies going direct-to-consumer, especially with those GLP-1 diabetes and weight-loss drugs.**ALEX:** The international segment was interesting too. Despite all the geopolitical challenges - trade wars, Middle East conflicts affecting airspace - they actually outperformed expectations. Revenue grew 3.8% to $4.5 billion.**JORDAN:** That's impressive given the headwinds. Their China-to-US trade lane, which is their most profitable international route, was still down 18.3%. But here's the key insight from the call: trade doesn't stop, it just moves. They're seeing volume growth in other parts of the world as supply chains adapt.**ALEX:** Now let's talk about the controversial part - this "Driver Choice" buyout program. They offered voluntary buyouts to reduce about 7,500 full-time driver positions, and it was apparently oversubscribed.**JORDAN:** This is where the human element of these corporate transformations really hits home. UPS says they needed to right-size their workforce for the new volume levels after the Amazon reduction. The program was oversubscribed, meaning more drivers wanted to take the buyout than UPS could accept.**ALEX:** The financial impact is significant. CFO Brian Dykes mentioned about $350 million in transitional costs in Q1, including this driver program, aircraft lease expenses, and weather-related costs. But they expect these costs to largely disappear in Q2.**JORDAN:** Which brings us to guidance. They're sticking with their full-year targets: $89.7 billion in revenue and a 9.6% operating margin. BuThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into S&P Global's first quarter 2026 results. This one's particularly interesting given the backdrop of geopolitical tensions and the company's aggressive AI push.Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Jordan, S&P Global just reported some pretty solid numbers despite what CEO Martina Cheung called an "incredibly volatile and dynamic operating environment." Walk us through the headline numbers.**JORDAN**: Absolutely, Alex. These results really showcase the resilience of S&P Global's business model. They posted 10% revenue growth year-over-year, with 9% organic constant currency growth. What really caught my eye was the 14% jump in adjusted diluted EPS and 140 basis points of margin expansion on a trailing twelve-month basis. That's impressive operating leverage.**ALEX**: And they returned a billion dollars to shareholders through share repurchases alone, on top of dividends. But let's talk about the elephant in the room - this Iranian conflict that's been disrupting energy markets. How did that impact their different divisions?**JORDAN**: Great question. The conflict created this interesting tale of two cities within S&P Global. On one hand, their Energy division faced direct headwinds - they actually lowered their full-year guidance for that segment by a full percentage point to 4.5% to 6% organic growth. CEO Cheung mentioned that some Middle Eastern energy customers had facilities directly impacted, and supply chain disruptions are expected to persist through the second quarter.But here's what's fascinating - this volatility actually benefited other parts of the business. Their Ratings division saw 13% revenue growth, partly driven by what they called "hyperscaler" issuance - basically big tech companies issuing debt for AI infrastructure investments.**ALEX**: That's a perfect segue into what I think is the real story here - S&P Global's AI transformation. Jordan, they're not just talking about using AI internally; they're fundamentally changing how customers access their data. Can you break down this strategy?**JORDAN**: This is where it gets really interesting, Alex. S&P Global is essentially becoming an AI-native data company. They're making their data accessible through what they call "model context protocol" - basically allowing customers to use S&P data directly within AI platforms like Claude and ChatGPT.The numbers they shared are eye-popping. API call volumes were 5x higher in Q1 versus just one quarter earlier, and doubled month-over-month from February to March alone. They now have over 300 customers either contracted or in trial periods for their AI-ready APIs.**ALEX**: And they're seeing real pricing power from this AI integration, right?**JORDAN**: Exactly. This is where the monetization story gets compelling. During the quarter, two financial clients opted to pay 35% to 45% premium increases just to get their data in AI-ready formats. CFO Eric Aboaf mentioned that customers using their AI solutions are showing much higher growth rates - 30% higher in Market Intelligence and double the growth rate in Energy compared to non-AI customers.One example really stood out to me: they had a buy-side client working with their Kensho AI team who liked their AI plugin so much that they canceled their existing provider and switched to S&P Global, even though it was 20% more expensive.**ALEX**: Let's talk about the guidance. They maintained most of their full-year outlook despite the geopolitical headwinds. What should investors expect for the rest of 2026?**JORDAN**: S&P Global is stiThis episode includes AI-generated content.

# Beta Finch Podcast Script: Coca-Cola Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're breaking down Coca-Cola's Q1 2026 earnings - and folks, this was a strong start to the year for the beverage giant.Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And what a quarter this was for Coca-Cola! Let me hit you with the headline numbers first. The company delivered 10% organic revenue growth with 3% volume growth across all segments. That's particularly impressive when you consider the challenging macro environment we're seeing globally.**ALEX**: Absolutely. And Jordan, what really caught my attention was the earnings per share performance - 18% growth to 86 cents per share on a comparable basis. That's solid double-digit growth that beat expectations. CEO Henrique Braun seemed pretty confident about their "balanced growth algorithm" approach.**JORDAN**: Right, and that's a key theme throughout this call - this idea of balancing volume growth with price/mix improvements. They managed 3% volume growth and 2% price/mix growth in Q1, which Braun described as exactly the kind of balanced approach they're targeting. He mentioned they might see this flip to 2% volume and 3% price/mix in other quarters, but the goal is maintaining that balance.**ALEX**: Now, there were some interesting regional dynamics here. North America showed solid performance with volume and value share gains, but they had some headwinds from Easter timing and category mix issues, particularly with packaged water and production constraints on Topo Chico and Fairlife.**JORDAN**: And speaking of Fairlife - which investors have been watching closely - Braun confirmed that the Webster facility capacity is coming online in Q2 as planned, which should help address those production constraints. That's a key capacity expansion for their growing dairy business.**ALEX**: Let's talk about some of the geographic highlights because this really shows Coke's global reach. In Latin America, they gained value share despite challenges in Mexico from the sugar tax that was implemented at the beginning of the year. But Brazil and Central America more than offset those declines.**JORDAN**: And in EMEA - that's Europe, Middle East, and Africa - they gained value share and grew volume across all operating units, despite some obvious challenges from the Middle East conflict. Braun noted that while they grew volume for the quarter overall, volumes did decline in March after the onset of that conflict.**ALEX**: The Asia Pacific region is particularly interesting from a strategic standpoint. They grew volume across all operating units despite cycling a tough comparison from the prior year. But Jordan, the margin story there was concerning - operating margins compressed almost 10 percentage points.**JORDAN**: That's right Alex, and CFO John Murphy addressed this directly. About two-thirds of that margin compression was due to a one-time inventory issue, particularly phasing of juice inventory costs in China. They also had commodity pressures in tea and coffee businesses. Murphy emphasized this was largely a Q1 anomaly and they expect improvement as the year progresses.**ALEX**: One thing that really stood out in the Q&A was the discussion around innovation and consumer centricity. Braun talked about their "4 I's" approach - insight, innovation, intimacy, and integrated execution. They highlighted the success of Coca-Cola Zero-Zero in Europe, which targets consumers who want to reduce caffeine intake in the evening.**JORDAN**: That'sThis episode includes AI-generated content.

# Beta Finch Podcast Script: American Tower (AMT) Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.**JORDAN**: And I'm Jordan. Today we're diving into American Tower's Q1 2026 results - and folks, this one's got some interesting twists.**ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. Now Alex, American Tower - AMT - is one of the biggest tower companies in the world, and they just reported what I'd call a solid but not spectacular quarter. What caught your attention first?**ALEX**: Well, they raised guidance across the board, which is always nice to see. But when you dig into the numbers, it's really about foreign exchange tailwinds and some accounting stuff rather than explosive underlying growth. Property revenue guidance went up by about $145 million at the midpoint - sounds great until you realize $110 million of that is just FX helping them out.**JORDAN**: Right, and there's this whole DISH situation hanging over everything. They've basically written DISH out of their numbers completely because of ongoing litigation. CEO Steven Vondran was pretty clear - they think their contract is enforceable, but they've "completely derisked" their guidance by excluding DISH entirely.**ALEX**: That's a smart move from a guidance perspective. Any upside from DISH is just gravy at this point. But let's talk about the real growth drivers. What's interesting is their data center business - CoreSite - is absolutely on fire. 17% growth when you strip out the accounting noise.**JORDAN**: CoreSite is fascinating because it's not just a traditional data center play. Vondran kept emphasizing it's really an "interconnection hub" - people come there to connect to other people, cloud providers, and now AI inference services. They're seeing what they call an "inflection in interconnection activity," which is basically their secret sauce for higher margins.**ALEX**: And they're doubling down on it. Over $700 million in growth capital planned for CoreSite to build out capacity. They're buying land, securing power, even looking at new markets - though Vondran wouldn't spill details on where.**JORDAN**: The AI angle is particularly interesting. They're not just riding the AI wave passively - they're positioning CoreSite as the place where AI workloads want to be because of all those interconnections. It's like being the popular kid at school that everyone wants to hang out with.**ALEX**: Ha! That's actually a pretty good analogy. Now on the traditional tower side, organic growth was around 4% when you adjust for the DISH mess - solid but not spectacular. What stood out to me was their commentary about potentially getting back into new tower construction in the U.S.**JORDAN**: Yeah, that was intriguing. They've been pretty quiet on U.S. build-to-suit for a while, but Vondran hinted they're having conversations with carriers about it. Meanwhile, they're actively building in Europe - 700 new sites planned there. The economics seem to work better overseas right now.**ALEX**: Let's talk about the elephant in the room - all the M&A speculation in the tower space. When asked about potential deals, Vondran was diplomatically non-committal but said they look at "everything." No strategic imperative to overpay, though.**JORDAN**: I loved his response to the question about what it means if competitors go private. Basically said they don't run their business based on what others are doing, but acknowledged the valuation disconnect between public and private markets. Very measured response.**ALEX**: The satellite question was interesting too. David Barden asked about SpaceX potentially disrupting teThis episode includes AI-generated content.

# Beta Finch Podcast Script - Intel Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex.**JORDAN:** And I'm Jordan. Today we're unpacking Intel's first quarter 2026 results, and wow - what a turnaround story this is becoming.**ALEX:** Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. Now Alex, let's talk about Intel because this earnings call felt like listening to a completely different company than we were hearing from just a year ago.**ALEX:** You're not wrong, Jordan. CEO Lip Bu Tan literally said "A year ago, the conversation about Intel Corporation was about whether we could survive. Today, it's about how quickly we can add manufacturing capacity." That's quite the transformation narrative.**JORDAN:** The numbers certainly back that up. Intel delivered $13.6 billion in revenue for Q1, which was $1.4 billion above the midpoint of their guidance. That's their sixth consecutive quarter of beating expectations. EPS came in at 29 cents versus guidance of breakeven.**ALEX:** And here's what really caught my attention - they're saying demand is outpacing supply across all their businesses, especially in server CPUs. CFO Dave Zinsner said they're missing out on revenue that "starts with a 'b'" - meaning billions in unmet demand.**JORDAN:** That supply constraint story is fascinating because it's driven by what they're calling the AI infrastructure buildout. Let's break down their segments. Data Center and AI revenue hit $5.1 billion, up 22% year-over-year, with ASIC revenue doubling. Meanwhile, Client Computing was $7.7 billion.**ALEX:** The AI story Intel is telling is particularly interesting. They're positioning CPUs as becoming more critical as AI moves from training to inference and into what they call "agentic" applications. Lip Bu mentioned that the ratio of CPUs to GPUs used to be 1-to-8, but it's moving toward 1-to-4 and could reach parity.**JORDAN:** That's a massive shift if it plays out. And they're backing it up with some big partnerships. They announced a multiyear deal with Google and this intriguing collaboration with Elon Musk's companies - SpaceX, xAI, and Tesla - for something called "TeraFab."**ALEX:** The Elon partnership is pretty wild. Lip Bu said they both believe global semiconductor supply isn't keeping pace with demand, and they want to "explore innovative ways to refactor silicon process technology." Very typical Elon - thinking outside the box on manufacturing efficiency.**JORDAN:** Let's talk about their foundry business because that's been the big question mark. Intel Foundry revenue was $5.4 billion, up 20% sequentially, though they're still losing $2.4 billion operationally. But here's the key - their 18A process node is running ahead of internal projections.**ALEX:** Right, and they're getting more confident about external foundry customers. Dave Zinsner said their advanced packaging backlog is now in the "billions of dollars" range, not the hundreds of millions they initially expected. That's a significant scale-up.**JORDAN:** The guidance for Q2 is solid too - $13.8 to $14.8 billion revenue, with both client and data center segments expected to grow sequentially. Though they are warning about PC market weakness in the second half and some margin pressure from ramping 18A production.**ALEX:** Speaking of margins, gross margin came in at 41% for Q1, way ahead of guidance, though they're guiding 39% for Q2. The 18A ramp is creating some near-term headwinds, but the volume growth and yield improvements are helping offset that.**JORDAN:** There was an interesting exchange in the Q&A about competiThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that matter. I'm Alex.JORDAN: And I'm Jordan. Today we're diving into Thermo Fisher Scientific's Q1 2026 earnings, and let me tell you, this one's got some interesting moving parts.ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Absolutely. So Alex, TMO just reported their first quarter results, and on the surface, it looks like a pretty solid performance. What caught your attention first?ALEX: Well, the headline numbers are decent but not spectacular. Revenue grew 6% to $11.01 billion, and adjusted EPS came in at $5.44, also up 6%. But here's the kicker - they actually beat their own guidance by 14 cents per share on the earnings side.JORDAN: That's a nice beat. And they're raising full-year guidance too, right? New revenue range of $47.3 to $48.1 billion, up from the previous $46.3 to $47.2 billion range.ALEX: Exactly. And on earnings, they're now expecting $24.64 to $25.12 per share, up from their original $24.22 to $24.80 guide. That represents 8% to 10% growth for the year. But Jordan, there's a big asterisk here - a lot of this guidance raise comes from their massive Clario acquisition.JORDAN: Right, the $9 billion elephant in the room. They closed that deal in late March. Clario is a digital endpoint data solutions company that complements their clinical research business. Even though it was only in the results for a few days, it contributed $30 million in revenue and a penny per share to Q1.ALEX: And CEO Marc Casper was pretty excited about it on the call. He kept talking about how it enhances their "trusted partner status" with pharma and biotech customers. The integration seems to be going smoothly, and customers are apparently enthusiastic about combining Thermo's capabilities with Clario's digital endpoints technology.JORDAN: Speaking of pharma and biotech, that was actually their strongest end market in the quarter with mid-single digit growth. Casper highlighted strength in bioproduction and clinical research. But let's talk about the headwinds they're facing.ALEX: Yeah, this is where it gets interesting. They had some real operational challenges. First, they had one less selling day compared to last year, which dinged organic growth by about a percentage point. Then there was revenue phasing in pharma services - another roughly one-point headwind.JORDAN: So if you normalize for those factors, their 1% organic growth in Q1 would have been closer to 3%. And that's exactly what they're guiding for in Q2. The concern from analysts on the call was about this acceleration they need in the back half of the year to hit their full-year 3-4% organic growth target.ALEX: Casper seemed pretty confident though. He said the markets are playing out exactly as expected, and the ramp isn't really assuming any change in underlying market conditions. It's more about these timing issues and comparisons normalizing.JORDAN: Let's break down the segments because there were some real divergences. Life Sciences Solutions was the star with 13% reported growth, though only 1% organic. That was driven by their bioproduction business having "another quarter of excellent organic growth," as CFO Stephen Williamson put it.ALEX: Meanwhile, Analytical Instruments was flat on revenue with organic declining 2%. This is the ongoing story we've been hearing across the industry - weak academic and government spending, especially in the US and China. Margins in that segment got hit hard, down 250 basis points to 20.7%.JORDAN: Ouch. And a lot of that margin pressure was from tariffs and foreign exchange headwinds. Williamson quantified the tariffThis episode includes AI-generated content.

# Beta Finch Podcast Script: ServiceNow Q1 2026 Earnings**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into ServiceNow's Q1 2026 results, and wow - there's a lot to unpack here.**JORDAN:** There really is, Alex. And before we jump in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX:** Thanks for that, Jordan. So let's start with the headline numbers because ServiceNow delivered what CEO Bill McDermott called a "beat and raise" quarter.**JORDAN:** Right, they beat across the board. Subscription revenue hit $3.67 billion, growing 19% year-over-year in constant currency - that's above the high end of their guidance. And their remaining performance obligations, or RPO, grew 23.5% to $27.7 billion. That's a massive backlog of contracted revenue.**ALEX:** The numbers are solid, but what's really interesting is the AI story here. McDermott dropped a pretty big bombshell on the call - they're now forecasting $1.5 billion in AI-specific commitments for 2026, up from their original $1 billion target. That's a 50% increase!**JORDAN:** That's huge, Alex. And it's not just talk - they're seeing real traction. Now Assist, their AI product suite, had deals with 3 or more products growing nearly 70% year-over-year. They had 36 deals with 5 or more AI products. Customers are clearly moving beyond just experimenting with AI.**ALEX:** Let's talk about their M&A strategy because they've been very active. They just closed three major acquisitions - Moveworks, Veza, and Armis. McDermott was particularly excited about the Moveworks integration.**JORDAN:** Yeah, the Moveworks story is pretty remarkable. They integrated it with their employee experience platform in just three weeks and rebranded it as "Employee Works." In Q1 alone, they closed more deals than Moveworks did in their entire previous year. That's execution at its finest.**ALEX:** And then there's Armis, which McDermott called their potential "Instagram" - referring to how that acquisition transformed Facebook. Armis brings cybersecurity visibility across IT, operational technology, and IoT devices. Given that cybercrime is now a trillion-dollar economy, the timing seems perfect.**JORDAN:** What I found fascinating was McDermott's framing of their "AI control tower for business reinvention." They're positioning ServiceNow as the orchestration layer that manages both human workers and AI agents. With 2.2 billion more AI agents expected in the workforce over the next few years, that's a massive opportunity.**ALEX:** The technical differentiation is interesting too. They're emphasizing their "context engine" - basically, 22 years of enterprise workflow data training their AI. As McDermott put it, "There's a perfect correlation between enterprise AI from any source and ServiceNow's expansion."**JORDAN:** Speaking of expansion, their hybrid pricing model is gaining traction. Fifty percent of new business now comes from non-seat-based pricing, including usage-based models. That's important because it lets them scale with AI adoption rather than just traditional user growth.**ALEX:** Now, let's address the elephant in the room - the stock dropped about 12% after hours despite these strong results. One analyst pressed them on this disconnect.**JORDAN:** Yeah, Keith Weiss from Morgan Stanley asked a great question about when ServiceNow will participate in the AI boom in a way that's more analogous to the big AI labs that are seeing massive revenue spikes. There seems to be some investor anxiety about whether ServiceNow is capturing enough of the AI spending.**ALEX:** McDermott's response was pretty passionate. He emphasized that tThis episode includes AI-generated content.

# Beta Finch Podcast Script - NextEra Energy (NEE) Q1 2026 Earnings---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly results so you don't have to. I'm Alex, and joining me as always is Jordan. Today we're diving into NextEra Energy's Q1 2026 earnings - and wow, Jordan, this utility giant is really making some bold moves in the AI and data center space.**JORDAN**: Absolutely, Alex. Before we jump in though, I want to remind our listeners that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks Jordan. So let's start with the numbers - NextEra posted adjusted earnings per share growth of 10% year-over-year, which is solid for a utility. But the real story here isn't just the financials, it's this massive pivot toward serving data centers and hyperscalers. Jordan, what caught your attention first?**JORDAN**: What jumped out at me was the sheer scale of opportunity they're talking about. Alex, they mentioned 21 gigawatts of large-load interest at their Florida Power & Light subsidiary alone - that's enormous. To put that in perspective, they're in advanced discussions on about 12 gigawatts of that, which could start being served as soon as 2028. And here's the kicker - every gigawatt under their approved tariff represents roughly $2 billion in capital expenditures.**ALEX**: That's massive capital deployment potential. But what really struck me was this U.S.-Japan deal they announced. Can you break that down for listeners?**JORDAN**: This is fascinating, Alex. The U.S. Department of Commerce selected NextEra to build 9.5 gigawatts of new gas-fired generation - one project in Texas, one in Pennsylvania - connected to Japan's $550 billion investment commitment to the United States. But here's what makes it brilliant: it's essentially a capital-light model for NextEra. The U.S. and Japan would own the projects while NextEra develops, builds, and operates them.**ALEX**: So they get the fees without the massive capital outlay risk. That's smart positioning. Speaking of positioning, their CEO John Ketchum kept emphasizing this "bring your own generation" or BYOG model. What's that about?**JORDAN**: This is NextEra's answer to a major political and economic challenge, Alex. Essentially, when hyperscalers like Google or Microsoft want massive amounts of power for their data centers, NextEra builds the infrastructure specifically for them - and they pay for it. Regular consumers don't subsidize these massive power needs through their electric bills. It's politically savvy and economically sound.**ALEX**: And they're not just talking about traditional power generation. They mentioned this collaboration with NVIDIA that sounds almost futuristic.**JORDAN**: Right! They're essentially treating data centers like giant batteries. The idea is that during extreme weather - think hot summer days or cold winter snaps when power demand spikes - they could temporarily reduce or shift data center computing activity. That freed-up power could then serve regular customers when electricity is scarce and expensive. It's a really innovative approach to grid management.**ALEX**: Let's talk about their AI initiative called "Rewire." This seems like a utility company trying to become a tech company.**JORDAN**: It's ambitious, Alex. They're partnering with Google Cloud to develop AI tools for the entire utility industry. They mentioned products like "Conduit" which uses AI to make their renewables workforce more efficient, and "Grid Composer" which optimizes power generation decisions in real-time. The goal is to drive costs even lower - they're already 30% below the national average in Florida.**ALEX**: The scale of their renewable energy business is also impressive. TheyThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the latest corporate results so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Lam Research's Q3 2026 earnings call, and wow, what a quarter this was for the semiconductor equipment giant.But before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex, and you're absolutely right about this being a standout quarter. Lam just posted their third consecutive record revenue quarter at $5.84 billion - that's up 9% sequentially and a massive 24% year-over-year. But the real headline here might be their Customer Support Business Group hitting $2 billion in quarterly revenue for the first time ever.**ALEX:** That's incredible growth, and what's really catching my attention is how CEO Tim Archer talked about this AI-driven semiconductor boom. Jordan, they actually raised their wafer fabrication equipment spending forecast from $135 billion to $140 billion for 2026, and Archer said there's a "bias to the upside." What's driving this optimism?**JORDAN:** It's all about AI demand creating this perfect storm for Lam. Think about it - AI workloads need more advanced memory, more complex chip architectures, and that means more deposition and etching processes, which is exactly Lam's sweet spot. Archer mentioned their served available market as a percentage of total wafer fab equipment spending is expanding to the "mid-30s percent" and heading toward the "high 30s" in the coming years.**ALEX:** And speaking of memory, there was some fascinating commentary about NAND flash memory. Apparently, AI is changing the entire storage landscape. Archer said they expect total data center memory bits this year to exceed both PC and mobile segments combined. That's a massive shift.**JORDAN:** Absolutely, and here's where it gets really interesting for Lam's business. They had previously said that about $40 billion in conversion spending would be needed over several years to upgrade existing NAND capacity to produce devices with more than 200 layers. Now they're saying that conversion is being "pulled forward" with most of the spending happening before the end of 2027. That's a significant acceleration.**ALEX:** Let's talk profitability because the numbers here are impressive. Gross margins hit 49.9% - at the high end of guidance - and they're guiding for 50.5% next quarter. CFO Doug Bettinger attributed this to improved factory efficiencies and better tool performance. Jordan, what stood out to you about their operational improvements?**JORDAN:** What I found fascinating was how they're leveraging technology to drive these margins. They talked about their Dextro cobots - these are automated maintenance robots - and their Equipment Intelligence services. Archer mentioned that customers using Dextro in production are seeing higher output and in some cases improved yield from existing capacity. That's the kind of value-add service that commands premium pricing.**ALEX:** The geographical breakdown was interesting too. China came in at 34% of revenue, but Bettinger expects that to decline in the June quarter. Meanwhile, both Korea and Taiwan hit record revenue levels at 23% each. It seems like the growth is really coming from leading-edge customers outside of China.**JORDAN:** Right, and that ties into their technology leadership story. During the Q&A, there was this great example where a customer actually switched to Lam's tools in the middle of their production ramp because of "superior defect performance and better yield." That's exactly the kind of competitive positioning you want in a supply-cThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex corporate calls into clear insights. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into IBM's Q1 2026 earnings - and wow, what a quarter this was for Big Blue.**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. Now Alex, IBM just posted some pretty impressive numbers. Walk us through the highlights.**ALEX:** The numbers really tell a story of transformation, Jordan. Revenue grew 6% to kick off 2026, but here's what caught my eye - free cash flow jumped 13% to $2.2 billion. That's their highest first quarter free cash flow in a decade.**JORDAN:** And when you dig into the segments, you see why CEO Arvind Krishna was so confident on this call. Software revenue grew 8%, with their data business absolutely crushing it at 16% growth. Infrastructure was up 12%, and get this - their mainframe business grew 48%.**ALEX:** That mainframe number is wild. And here's something fascinating from Krishna's commentary - he talked about how AI is creating entirely new use cases for mainframes. Instead of sampling just 10% of transactions for fraud detection, banks can now run AI inference on every single transaction directly on the platform.**JORDAN:** That's a perfect example of how IBM is positioning itself in the AI revolution. They're not trying to build the next ChatGPT - they're building the infrastructure that lets enterprises actually use AI securely with their own data. Krishna made this point beautifully when he said they're helping clients "put AI to work on their terms."**ALEX:** Speaking of AI positioning, one of the most interesting Q&A moments came when an analyst asked about IBM's software mix between infrastructure and applications. Krishna basically said only about 4% of their portfolio could be called applications - everything else is what he called "enabling software."**JORDAN:** Which is brilliant positioning for the AI era, right? As agents start replacing some human interactions, the value isn't going to be in that interaction layer - it's going to be in the underlying data and business logic. IBM saw this coming and positioned their portfolio accordingly.**ALEX:** Exactly. And the Confluent acquisition they closed early is a perfect example. This company streams live, governed data to AI models across hybrid environments. CFO Jim Kavanaugh said it should boost their data revenue by more than 15 percentage points.**JORDAN:** The guidance update was interesting too. They're now projecting software growth of 10-plus percent for the year, up from their previous 10% target. But they kept their overall revenue guidance at 5-plus percent growth and free cash flow growth of about $1 billion.**ALEX:** When analysts pressed them on why they didn't raise guidance after such a strong quarter, Kavanaugh had a great response. He said they've never raised guidance in the first quarter in his nine years as CFO, and they want to maintain their "beat mentality."**JORDAN:** That discipline is probably why the stock has performed so well. But there were some concerns raised. One analyst noted that Red Hat's RHEL business decelerated, which Kavanaugh attributed to federal government budget closures and supply chain disruptions in the hardware market.**ALEX:** The macro environment discussion was revealing too. Krishna said the Middle East actually had their strongest growth in decades - not years, decades. Europe was also strong. The only potential concern he flagged was if Middle East shipping routes stay disrupted for weeks, it could impact European energy costs.**JORDAN:** What struck me most was how thThis episode includes AI-generated content.